{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:25:04Z","timestamp":1783009504874,"version":"3.54.5"},"reference-count":274,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L244024"],"award-info":[{"award-number":["L244024"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473199"],"award-info":[{"award-number":["82473199"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing High-Level Innovation and Entrepreneurship Talent Support Program leading talent projects","award":["G202512054"],"award-info":[{"award-number":["G202512054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10353-y","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:13:53Z","timestamp":1783008833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HER2 assessment in urothelial carcinoma: standardization challenges and the path forward"],"prefix":"10.1007","volume":"45","author":[{"given":"Peipei","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Citing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-0975","authenticated-orcid":false,"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"3","key":"10353_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10353_CR2","doi-asserted-by":"publisher","unstructured":"Masson-Lecomte, A., Birtle, A., Pradere, B., Capoun, O., Comp\u00e9rat, E., Dom\u00ednguez-Escrig, J. L., \u2026 & Gontero, P. (2025). European association of urology guidelines on upper urinary tract urothelial carcinoma: Summary of the 2025 update. European Urology, 87(6), 697\u2013716. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.023","DOI":"10.1016\/j.eururo.2025.02.023"},{"issue":"10","key":"10353_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","volume":"21","author":"G Roviello","year":"2024","unstructured":"Roviello, G., Santoni, M., Sonpavde, G. P., & Catalano, M. (2024). The evolving treatment landscape of metastatic urothelial cancer. Nature Reviews Urology, 21(10), 580\u2013592. https:\/\/doi.org\/10.1038\/s41585-024-00872-0","journal-title":"Nature Reviews Urology"},{"issue":"8","key":"10353_CR4","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/molecules29081896","volume":"29","author":"A Eturi","year":"2024","unstructured":"Eturi, A., Bhasin, A., Zarrabi, K. K., & Tester, W. J. (2024). Predictive and prognostic biomarkers and tumor antigens for targeted therapy in urothelial carcinoma. Molecules, 29(8), 1896. https:\/\/doi.org\/10.3390\/molecules29081896","journal-title":"Molecules"},{"key":"10353_CR5","doi-asserted-by":"publisher","unstructured":"Raggi, D., Crupi, E., Pederzoli, F., Martini, A., Briganti, A., Alhalabi, O., \u2026 & Galsky, M. D. (2025). HER2 and urothelial carcinoma: Current understanding and future directions. Nature Reviews Urology, 23(2), 110\u2013132. https:\/\/doi.org\/10.1038\/s41585-025-01075-x","DOI":"10.1038\/s41585-025-01075-x"},{"key":"10353_CR6","doi-asserted-by":"publisher","unstructured":"Zhou, L., Yang, K. W., Zhang, S., Yan, X. Q., Li, S. M., Xu, H. Y., \u2026 & Sheng, X. (2025). Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): A phase ib\/II dose-escalation and dose-expansion study. Annals of Oncology, 36(3), 331\u2013339. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.002","DOI":"10.1016\/j.annonc.2024.12.002"},{"key":"10353_CR7","doi-asserted-by":"publisher","unstructured":"Yang, M., Yao, Y., Wang, K., Qi, L., Yang, B., Khudadad, M., \u2026 & Cao, W. (2025). Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: A retrospective single-center experience in China. Virchows Archiv. https:\/\/doi.org\/10.1007\/s00428-025-04057-x","DOI":"10.1007\/s00428-025-04057-x"},{"key":"10353_CR8","doi-asserted-by":"publisher","unstructured":"Albarr\u00e1n, V., Rosero, D. I., Chamorro, J., Pozas, J., San Rom\u00e1n, M., Barrill, A. M., \u2026 & Gajate, P. (2022). Her-2 targeted therapy in advanced urothelial cancer: From monoclonal antibodies to antibody-drug conjugates. International Journal of Molecular Sciences, 23(20), 12659. https:\/\/doi.org\/10.3390\/ijms232012659","DOI":"10.3390\/ijms232012659"},{"key":"10353_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1011885","volume":"12","author":"E Scherrer","year":"2022","unstructured":"Scherrer, E., Kang, A., Bloudek, L. M., & Koshkin, V. S. (2022). HER2 expression in urothelial carcinoma, a systematic literature review. Frontiers in Oncology, 12, Article 1011885. https:\/\/doi.org\/10.3389\/fonc.2022.1011885","journal-title":"Frontiers in Oncology"},{"key":"10353_CR10","doi-asserted-by":"publisher","unstructured":"Zhu, K., Chang, Y., Zhao, D., Guo, A., Cao, J., Wu, C., \u2026 & Ding, S. (2024). Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients. Frontiers in Pharmacology, 15, 1355081. https:\/\/doi.org\/10.3389\/fphar.2024.1355081","DOI":"10.3389\/fphar.2024.1355081"},{"key":"10353_CR11","doi-asserted-by":"publisher","first-page":"pp. 123","DOI":"10.1016\/bs.acc.2019.03.004","volume-title":"Advances in clinical chemistry","author":"Y Chen","year":"2019","unstructured":"Chen, Y., Liu, L., Ni, R., & Zhou, W. (2019). Advances in HER2 testing. Advances in clinical chemistry (Vol. Vol. 91, pp. 123\u2013162). Elsevier. https:\/\/doi.org\/10.1016\/bs.acc.2019.03.004"},{"key":"10353_CR12","doi-asserted-by":"publisher","unstructured":"Hashimoto, M., Fujita, K., Tomiyama, E., Fujimoto, S., Adomi, S., Banno, E., \u2026 & Uemura, H. (2023). Immunohistochemical analysis of HER2, EGFR, and Nectin-4 expression in upper urinary tract urothelial carcinoma. Anticancer Research, 43(1), 167\u2013174. https:\/\/doi.org\/10.21873\/anticanres.16146","DOI":"10.21873\/anticanres.16146"},{"issue":"10","key":"10353_CR13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3760\/cma.j.cn112152-20210809-00597","volume":"43","author":"Tumor Pathology Committee of Chinese Anti-Cancer Association & Expert Committee on Urothelial Carcinoma of Chinese Society of Clinical Oncology","year":"2021","unstructured":"Tumor Pathology Committee of Chinese Anti-Cancer Association & Expert Committee on Urothelial Carcinoma of Chinese Society of Clinical Oncology. (2021). Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China. Zhonghua zhong liu za zhi [Chinese Journal of Oncology], 43(10), 1001\u20131006. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20210809-00597","journal-title":"Zhonghua zhong liu za zhi [Chinese Journal of Oncology]"},{"key":"10353_CR14","doi-asserted-by":"publisher","unstructured":"Bai, X., Sun, P., Wang, X., Long, C., Liao, S., Dang, S., \u2026 & Zhang, Z. (2023). Structure and dynamics of the EGFR\/HER2 heterodimer. Cell Discovery, 9(1), 18. https:\/\/doi.org\/10.1038\/s41421-023-00523-5","DOI":"10.1038\/s41421-023-00523-5"},{"issue":"7","key":"10353_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/genes15070903","volume":"15","author":"X Cheng","year":"2024","unstructured":"Cheng, X. (2024). A comprehensive review of HER2 in cancer biology and therapeutics. Genes, 15(7), 903. https:\/\/doi.org\/10.3390\/genes15070903","journal-title":"Genes"},{"issue":"24","key":"10353_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038508","volume":"103","author":"L Pan","year":"2024","unstructured":"Pan, L., Li, J., Xu, Q., Gao, Z., Yang, M., Wu, X., & Li, X. (2024). HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: A review. Medicine, 103(24), Article e38508. https:\/\/doi.org\/10.1097\/MD.0000000000038508","journal-title":"Medicine"},{"issue":"7","key":"10353_CR17","first-page":"1476","volume":"7","author":"S Matkar","year":"2017","unstructured":"Matkar, S., An, C., & Hua, X. (2017). Kinase inhibitors of HER2\/AKT pathway induce ERK phosphorylation via a FOXO-dependent feedback loop. American Journal of Cancer Research, 7(7), 1476\u20131485.","journal-title":"American Journal of Cancer Research"},{"issue":"12","key":"10353_CR18","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/bjc.2011.163","volume":"104","author":"R Mukherjee","year":"2011","unstructured":"Mukherjee, R., McGuinness, D. H., McCall, P., Underwood, M. A., Seywright, M., Orange, C., & Edwards, J. (2011). Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. British Journal of Cancer, 104(12), 1920\u20131928. https:\/\/doi.org\/10.1038\/bjc.2011.163","journal-title":"British Journal of Cancer"},{"key":"10353_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2019.05.025","volume":"459","author":"Z Cao","year":"2019","unstructured":"Cao, Z., Liao, Q., Su, M., Huang, K., Jin, J., & Cao, D. (2019). AKT and ERK dual inhibitors: The way forward? Cancer Letters, 459, 30\u201340. https:\/\/doi.org\/10.1016\/j.canlet.2019.05.025","journal-title":"Cancer Letters"},{"key":"10353_CR20","doi-asserted-by":"publisher","unstructured":"Schade, B., Lesurf, R., Sanguin-Gendreau, V., Bui, T., Deblois, G., O\u2019Toole, S. A., \u2026 & Muller, W. J. (2013). \u03b2-catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Research, 73(14), 4474\u20134487. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3925","DOI":"10.1158\/0008-5472.CAN-12-3925"},{"key":"10353_CR21","doi-asserted-by":"publisher","unstructured":"Itah, Z., Chaudhry, S., Raju Ponny, S., Aydemir, O., Lee, A., Cavanagh-Kyros, J., \u2026 & Davis, R. J. (2023). HER2-driven breast cancer suppression by the JNK signaling pathway. Proceedings of the National Academy of Sciences, 120(4), e2218373120. https:\/\/doi.org\/10.1073\/pnas.2218373120","DOI":"10.1073\/pnas.2218373120"},{"issue":"2","key":"10353_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1974","volume":"7","author":"L Li","year":"2024","unstructured":"Li, L., Zhang, Y., Yang, K., Liu, W., Zhou, Z., & Xu, Y. (2024). MiRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting ERBB2. Cancer Reports, 7(2), Article e1974. https:\/\/doi.org\/10.1002\/cnr2.1974","journal-title":"Cancer Reports"},{"issue":"8","key":"10353_CR23","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/onc.2009.410","volume":"29","author":"EC Merkhofer","year":"2010","unstructured":"Merkhofer, E. C., Cogswell, P., & Baldwin, A. S. (2010). Her2 activates NF-\u03baB and induces invasion through the canonical pathway involving IKK\u03b1. Oncogene, 29(8), 1238\u20131248. https:\/\/doi.org\/10.1038\/onc.2009.410","journal-title":"Oncogene"},{"key":"10353_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","volume":"79","author":"R Roskoski","year":"2014","unstructured":"Roskoski, R. (2014). The ErbB\/HER family of protein-tyrosine kinases and cancer. Pharmacological Research, 79, 34\u201374. https:\/\/doi.org\/10.1016\/j.phrs.2013.11.002","journal-title":"Pharmacological Research"},{"key":"10353_CR25","doi-asserted-by":"publisher","unstructured":"Hanker, A. B., Brown, B. P., Meiler, J., Mar\u00edn, A., Jayanthan, H. S., Ye, D., \u2026 & Arteaga, C. L. (2021). Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell, 39(8), 1099\u20131114.e8. https:\/\/doi.org\/10.1016\/j.ccell.2021.06.001","DOI":"10.1016\/j.ccell.2021.06.001"},{"key":"10353_CR26","doi-asserted-by":"publisher","unstructured":"Trenker, R., Diwanji, D., Bingham, T., Verba, K. A., & Jura, N. (2024). Structural dynamics of the active HER4 and HER2\/HER4 complexes is finely tuned by different growth factors and glycosylation. bioRxiv: The Preprint Server for Biology, 2023.10.06.561161. https:\/\/doi.org\/10.1101\/2023.10.06.561161","DOI":"10.1101\/2023.10.06.561161"},{"issue":"11","key":"10353_CR27","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.21037\/tau-24-354","volume":"13","author":"X Huang","year":"2024","unstructured":"Huang, X., Li, S., Yang, T., Ma, D., Cai, H., Xu, X., & Zhang, Y. (2024). Distinct clinical features of urothelial carcinoma with low-expressing human epidermal growth factor receptor 2 status. Translational Andrology and Urology, 13(11), 2419\u20132429. https:\/\/doi.org\/10.21037\/tau-24-354","journal-title":"Translational Andrology and Urology"},{"key":"10353_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.humpath.2016.07.014","volume":"57","author":"AL Goodman","year":"2016","unstructured":"Goodman, A. L., & Osunkoya, A. O. (2016). Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: An analysis of 27 cases. Human Pathology, 57, 160\u2013164. https:\/\/doi.org\/10.1016\/j.humpath.2016.07.014","journal-title":"Human Pathology"},{"key":"10353_CR29","doi-asserted-by":"publisher","unstructured":"Tschui, J., Vassella, E., Bandi, N., Baumgartner, U., Genitsch, V., Rotzer, D., \u2026 & Fleischmann, A. (2015). Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Archiv, 466(6), 703\u2013710. https:\/\/doi.org\/10.1007\/s00428-015-1729-4","DOI":"10.1007\/s00428-015-1729-4"},{"key":"10353_CR30","doi-asserted-by":"publisher","unstructured":"Wang, G., Wen, P., Xue, T., Huang, Y., Shao, Q., Zhang, N., \u2026 & Zeng, X. (2024). Her2 promotes early dissemination of breast cancer by inhibiting the p38 pathway through the downregulation of MAP3K4. Cell Communication and Signaling, 22(1), 611. https:\/\/doi.org\/10.1186\/s12964-024-02000-2","DOI":"10.1186\/s12964-024-02000-2"},{"key":"10353_CR31","doi-asserted-by":"publisher","unstructured":"Aumayr, K., Klatte, T., Neudert, B., Birner, P., Shariat, S., Schmidinger, M., \u2026 & Haitel, A. (2018). HER2 and TOP2A gene amplification and protein expression in upper tract urothelial carcinomas. Pathology & Oncology Research, 24(3), 575\u2013581. https:\/\/doi.org\/10.1007\/s12253-017-0260-0","DOI":"10.1007\/s12253-017-0260-0"},{"issue":"2","key":"10353_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1309\/41VLTFX3YPP1HF6F","volume":"130","author":"DE Hansel","year":"2008","unstructured":"Hansel, D. E., Swain, E., Dreicer, R., & Tubbs, R. R. (2008). HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. American Journal of Clinical Pathology, 130(2), 274\u2013281. https:\/\/doi.org\/10.1309\/41VLTFX3YPP1HF6F","journal-title":"American Journal of Clinical Pathology"},{"key":"10353_CR33","doi-asserted-by":"publisher","unstructured":"Aggen, D. H., Shah, N. J., Zheng, J., Alam, S. M., Balar, O., Niederhausern, A., \u2026 & Iyer, G. (2024). HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer. Journal of Clinical Oncology, 42(4_suppl), 538\u2013538. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.538","DOI":"10.1200\/JCO.2024.42.4_suppl.538"},{"key":"10353_CR34","doi-asserted-by":"publisher","unstructured":"Chen, Z., Tang, X., Eichholz, J. E., Mcpherson, A., Thomas, J., Nagar, K., \u2026 & Solit, D. B. (2025). Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer. Nature Communications, 17(1), 919. https:\/\/doi.org\/10.1038\/s41467-025-67643-2","DOI":"10.1038\/s41467-025-67643-2"},{"key":"10353_CR35","doi-asserted-by":"publisher","unstructured":"Li, B. T., Ross, D. S., Aisner, D. L., Chaft, J. E., Hsu, M., Kako, S. L., \u2026 & Arcila, M. E. (2016). HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. Journal of Thoracic Oncology, 11(3), 414\u2013419. https:\/\/doi.org\/10.1016\/j.jtho.2015.10.025","DOI":"10.1016\/j.jtho.2015.10.025"},{"key":"10353_CR36","doi-asserted-by":"publisher","unstructured":"Posada, J. M., Yakirevich, E., Kamat, A. M., Sood, A., Jacob, J. M., Bratslavsky, G., \u2026 & Cheng, L. (2024). Characterizing the genomic landscape of the micropapillary subtype of urothelial carcinoma of the bladder harboring activating extracellular mutations of ERBB2. Modern Pathology, 37(3), 100424. https:\/\/doi.org\/10.1016\/j.modpat.2024.100424","DOI":"10.1016\/j.modpat.2024.100424"},{"key":"10353_CR37","doi-asserted-by":"publisher","unstructured":"Nguyen, D. D., Hooper, W. F., Liu, W., Chu, T. R., Geiger, H., Shelton, J. M., \u2026 & Faltas, B. M. (2024). The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution. Nature, 635(8037), 219\u2013228. https:\/\/doi.org\/10.1038\/s41586-024-07955-3","DOI":"10.1038\/s41586-024-07955-3"},{"key":"10353_CR38","doi-asserted-by":"publisher","unstructured":"Dumbrava, E. E. I., Balaji, K., Raghav, K., Hess, K., Javle, M., Blum-Murphy, M., \u2026 & Meric-Bernstam, F. (2019). Targeting () amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. JCO Precision Oncology, (3), 1\u201312. https:\/\/doi.org\/10.1200\/PO.18.00345","DOI":"10.1200\/PO.18.00345"},{"key":"10353_CR39","unstructured":"Ning, S.-F., Li, J.-L., Luo, C.-P., Wei, C.-H., Lu, Y.-K., Liu, H.-Z., \u2026 & Zhang, L.-T. (2014). Human epidermal growth factor receptor 2 expression in breast cancer: Correlation with clinical pathological features. International Journal of Clinical and Experimental Pathology, 7(12), 8740\u20138747."},{"issue":"2","key":"10353_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4103\/IJPM.IJPM_535_20","volume":"65","author":"D Nergiz","year":"2022","unstructured":"Nergiz, D., Alikano\u011flu, A. S., S\u00fcren, D., G\u00f6mceli, \u0130, & \u00d6zt\u00fcrk, B. (2022). Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma. Indian Journal of Pathology & Microbiology, 65(2), 321\u2013327. https:\/\/doi.org\/10.4103\/IJPM.IJPM_535_20","journal-title":"Indian Journal of Pathology & Microbiology"},{"key":"10353_CR41","doi-asserted-by":"publisher","unstructured":"Wen, W., Chen, W. S., Xiao, N., Bender, R., Ghazalpour, A., Tan, Z., \u2026 & Press, M. F. (2015). Mutations in the kinase domain of the HER2\/ERBB2 gene identified in a wide variety of human cancers. The Journal of molecular diagnostics: JMD, 17(5), 487\u2013495. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.04.003","DOI":"10.1016\/j.jmoldx.2015.04.003"},{"key":"10353_CR42","doi-asserted-by":"publisher","unstructured":"Pahuja, K. B., Nguyen, T. T., Jaiswal, B. S., Prabhash, K., Thaker, T. M., Senger, K., \u2026 & Seshagiri, S. (2018). Actionable activating oncogenic ERBB2\/HER2 transmembrane and juxtamembrane domain mutations. Cancer Cell, 34(5), 792\u2013806.e5. https:\/\/doi.org\/10.1016\/j.ccell.2018.09.010","DOI":"10.1016\/j.ccell.2018.09.010"},{"key":"10353_CR43","doi-asserted-by":"publisher","unstructured":"Greulich, H., Kaplan, B., Mertins, P., Chen, T.-H., Tanaka, K. E., Yun, C.-H., \u2026 & Meyerson, M. (2012). Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proceedings of the National Academy of Sciences of the United States of America, 109(36), 14476\u201314481. https:\/\/doi.org\/10.1073\/pnas.1203201109","DOI":"10.1073\/pnas.1203201109"},{"key":"10353_CR44","doi-asserted-by":"publisher","unstructured":"Zabransky, D. J., Yankaskas, C. L., Cochran, R. L., Wong, H. Y., Croessmann, S., Chu, D., \u2026 & Park, B. H. (2015). HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America, 112(45), E6205\u20136214. https:\/\/doi.org\/10.1073\/pnas.1516853112","DOI":"10.1073\/pnas.1516853112"},{"key":"10353_CR45","doi-asserted-by":"publisher","unstructured":"Cousin, S., Khalifa, E., Crombe, A., Laizet, Y., Lucchesi, C., Toulmonde, M., \u2026 & Italiano, A. (2018). Targeting ERBB2 mutations in solid tumors: Biological and clinical implications. Journal of Hematology & Oncology, 11(1), 86. https:\/\/doi.org\/10.1186\/s13045-018-0630-4","DOI":"10.1186\/s13045-018-0630-4"},{"issue":"12","key":"10353_CR46","doi-asserted-by":"publisher","first-page":"e1303","DOI":"10.1634\/theoncologist.2018-0845","volume":"24","author":"J Subramanian","year":"2019","unstructured":"Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019). Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers. The Oncologist, 24(12), e1303\u2013e1314. https:\/\/doi.org\/10.1634\/theoncologist.2018-0845","journal-title":"The Oncologist"},{"key":"10353_CR47","doi-asserted-by":"publisher","unstructured":"Madison, R. W., Gupta, S. V., Elamin, Y. Y., Lin, D. I., Pal, S. K., Necchi, A., \u2026 & Ali, S. M. (2020). Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. BJU international, 125(5), 739\u2013746. https:\/\/doi.org\/10.1111\/bju.15006","DOI":"10.1111\/bju.15006"},{"key":"10353_CR48","doi-asserted-by":"publisher","unstructured":"Ross, J. S., Gay, L. M., Wang, K., Ali, S. M., Chumsri, S., Elvin, J. A., \u2026 & Stephens, P. J. (2016). Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Cancer, 122(17), 2654\u20132662. https:\/\/doi.org\/10.1002\/cncr.30102","DOI":"10.1002\/cncr.30102"},{"key":"10353_CR49","doi-asserted-by":"publisher","unstructured":"Kiss, B., Wyatt, A. W., Douglas, J., Skuginna, V., Mo, F., Anderson, S., \u2026 & Seiler, R. (2017). Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Scientific Reports, 7(1), 42713. https:\/\/doi.org\/10.1038\/srep42713","DOI":"10.1038\/srep42713"},{"key":"10353_CR50","doi-asserted-by":"publisher","unstructured":"Kurozumi, S., Alsaleem, M., Monteiro, C. J., Bhardwaj, K., Joosten, S. E. P., Fujii, T., \u2026 & Johnston, S. J. (2020). Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: A retrospective in silico analysis of public datasets. Breast cancer research: BCR, 22(1), 85. https:\/\/doi.org\/10.1186\/s13058-020-01324-4","DOI":"10.1186\/s13058-020-01324-4"},{"key":"10353_CR51","doi-asserted-by":"publisher","unstructured":"Zuo, W.-J., Jiang, Y.-Z., Wang, Y.-J., Xu, X.-E., Hu, X., Liu, G.-Y., \u2026 & Shao, Z.-M. (2016). Dual characteristics of novel HER2 kinase domain mutations in response to HER2-targeted therapies in human breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 22(19), 4859\u20134869. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3036","DOI":"10.1158\/1078-0432.CCR-15-3036"},{"key":"10353_CR52","doi-asserted-by":"publisher","unstructured":"de Martino, M., Zhuang, D., Klatte, T., Rieken, M., Roupr\u00eat, M., Xylinas, E., \u2026 & Shariat, S. F. (2014). Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biology & Therapy, 15(9), 1239\u20131247. https:\/\/doi.org\/10.4161\/cbt.29687","DOI":"10.4161\/cbt.29687"},{"key":"10353_CR53","doi-asserted-by":"publisher","first-page":"1012138","DOI":"10.3389\/fonc.2022.1012138","volume":"12","author":"H Wang","year":"2022","unstructured":"Wang, H., Jiang, Y., Jin, H., & Wang, C. (2022). ERBB2 promoter demethylation and immune cell infiltration promote a poor prognosis for cancer patients. Frontiers in Oncology, 12, 1012138. https:\/\/doi.org\/10.3389\/fonc.2022.1012138","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10353_CR54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/s0014-5793(01)02951-9","volume":"507","author":"SK Mishra","year":"2001","unstructured":"Mishra, S. K., Mandal, M., Mazumdar, A., & Kumar, R. (2001). Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells. FEBS letters, 507(1), 88\u201394. https:\/\/doi.org\/10.1016\/s0014-5793(01)02951-9","journal-title":"FEBS letters"},{"issue":"5","key":"10353_CR55","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/onc.2017.382","volume":"37","author":"Q Liu","year":"2018","unstructured":"Liu, Q., Kulak, M. V., Borcherding, N., Maina, P. K., Zhang, W., Weigel, R. J., & Qi, H. H. (2018). A novel HER2 gene body enhancer contributes to HER2 expression. Oncogene, 37(5), 687\u2013694. https:\/\/doi.org\/10.1038\/onc.2017.382","journal-title":"Oncogene"},{"key":"10353_CR56","doi-asserted-by":"publisher","unstructured":"Zhu, X., Chan, E., Turski, M. L., Mendez, C. E., Hsu, S. C., Kumar, V., \u2026 & Koshkin, V. S. (2024). HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. The Oncologist, 29(8), e1094\u2013e1097. https:\/\/doi.org\/10.1093\/oncolo\/oyae127","DOI":"10.1093\/oncolo\/oyae127"},{"issue":"3","key":"10353_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.79","volume":"4","author":"S Wang","year":"2013","unstructured":"Wang, S., Huang, J., Lyu, H., Lee, C.-K., Tan, J., Wang, J., & Liu, B. (2013). Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2\/erbB3 and apoptosis in breast cancer cells. Cell Death & Disease, 4(3), Article e556. https:\/\/doi.org\/10.1038\/cddis.2013.79","journal-title":"Cell Death & Disease"},{"issue":"3","key":"10353_CR58","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3892\/mmr.2017.6112","volume":"15","author":"L Cheng","year":"2017","unstructured":"Cheng, L., Zhan, B., Luo, P., & Wang, B. (2017). miRNA-375 regulates the cell survival and apoptosis of human non-small cell carcinoma by targeting HER2. Molecular Medicine Reports, 15(3), 1387\u20131392. https:\/\/doi.org\/10.3892\/mmr.2017.6112","journal-title":"Molecular Medicine Reports"},{"issue":"46","key":"10353_CR59","doi-asserted-by":"publisher","first-page":"6015","DOI":"10.1038\/onc.2016.132","volume":"35","author":"X-H He","year":"2016","unstructured":"He, X.-H., Zhu, W., Yuan, P., Jiang, S., Li, D., Zhang, H.-W., & Liu, M.-F. (2016). miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells. Oncogene, 35(46), 6015\u20136025. https:\/\/doi.org\/10.1038\/onc.2016.132","journal-title":"Oncogene"},{"key":"10353_CR60","doi-asserted-by":"publisher","unstructured":"Tan, S., Ding, K., Chong, Q.-Y., Zhao, J., Liu, Y., Shao, Y., \u2026 & Zhu, T. (2017). Post-transcriptional regulation of ERBB2 by miR26a\/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. The Journal of Biological Chemistry, 292(33), 13551\u201313564. https:\/\/doi.org\/10.1074\/jbc.M117.780973","DOI":"10.1074\/jbc.M117.780973"},{"key":"10353_CR61","doi-asserted-by":"publisher","unstructured":"Gu, Y., Gao, H., Zhang, H., John, A., Zhu, X., Shivaram, S., \u2026 & Wang, L. (2022). TRAF4 hyperactivates HER2 signaling and contributes to trastuzumab resistance in HER2-positive breast cancer. Oncogene, 41(35), 4119\u20134129. https:\/\/doi.org\/10.1038\/s41388-022-02415-6","DOI":"10.1038\/s41388-022-02415-6"},{"issue":"1","key":"10353_CR62","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1128\/MCB.00899-06","volume":"27","author":"W Xu","year":"2007","unstructured":"Xu, W., Yuan, X., Beebe, K., Xiang, Z., & Neckers, L. (2007). Loss of Hsp90 association up-regulates src-dependent ErbB2 activity. Molecular and Cellular Biology, 27(1), 220\u2013228. https:\/\/doi.org\/10.1128\/MCB.00899-06","journal-title":"Molecular and Cellular Biology"},{"issue":"12","key":"10353_CR63","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/sj.onc.1204205","volume":"20","author":"AP Belsches-Jablonski","year":"2001","unstructured":"Belsches-Jablonski, A. P., Biscardi, J. S., Peavy, D. R., Tice, D. A., Romney, D. A., & Parsons, S. J. (2001). Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene, 20(12), 1465\u20131475. https:\/\/doi.org\/10.1038\/sj.onc.1204205","journal-title":"Oncogene"},{"key":"10353_CR64","doi-asserted-by":"publisher","unstructured":"Zhu, J.-H., Chen, R., Yi, W., Cantin, G. T., Fearns, C., Yang, Y., \u2026 & Lee, J.-D. (2008). Protein tyrosine phosphatase PTPN13 negatively regulates Her2\/ErbB2 malignant signaling. Oncogene, 27(18), 2525\u20132531. https:\/\/doi.org\/10.1038\/sj.onc.1210922","DOI":"10.1038\/sj.onc.1210922"},{"issue":"26","key":"10353_CR65","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1056\/NEJMra1307118","volume":"383","author":"HJ Burstein","year":"2020","unstructured":"Burstein, H. J. (2020). Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. New England Journal of Medicine, 383(26), 2557\u20132570. https:\/\/doi.org\/10.1056\/NEJMra1307118","journal-title":"New England Journal of Medicine"},{"key":"10353_CR66","doi-asserted-by":"publisher","unstructured":"Atallah, N. M., Haque, M., Quinn, C., Toss, M. S., Makhlouf, S., Ibrahim, A., \u2026 & Rakha, E. (2023). Characterisation of luminal and triple-negative breast cancer with HER2 low protein expression. European Journal of Cancer, 195, 113371. https:\/\/doi.org\/10.1016\/j.ejca.2023.113371","DOI":"10.1016\/j.ejca.2023.113371"},{"key":"10353_CR67","doi-asserted-by":"publisher","unstructured":"Sotiriadou, R., Perez, S. A., Gritzapis, A. D., Sotiropoulou, P. A., Echner, H., Heinzel, S., \u2026 & Papamichail, M. (2001). Peptide HER2(776\u2013788) represents a naturally processed broad MHC class II-restricted T cell epitope. British Journal of Cancer, 85(10), 1527\u20131534. https:\/\/doi.org\/10.1054\/bjoc.2001.2089","DOI":"10.1054\/bjoc.2001.2089"},{"key":"10353_CR68","doi-asserted-by":"publisher","unstructured":"Wu, S., Zhang, Q., Zhang, F., Meng, F., Liu, S., Zhou, R., \u2026 & Xu, P. (2019). HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nature Cell Biology, 21(8), 1027\u20131040. https:\/\/doi.org\/10.1038\/s41556-019-0352-z","DOI":"10.1038\/s41556-019-0352-z"},{"key":"10353_CR69","doi-asserted-by":"publisher","unstructured":"Zidel, A., Benton, A., Brown, E., Shmuel, S., Vanover, A., Panikar, S. S., \u2026 & Pereira, P. M. R. (2025). Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer. Scientific Reports, 15(1), 16964. https:\/\/doi.org\/10.1038\/s41598-025-01947-7","DOI":"10.1038\/s41598-025-01947-7"},{"key":"10353_CR70","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Nogueira, P., Mancino, M., Fuster, G., L\u00f3pez-Plana, A., Jauregui, P., Almendro, V., \u2026 & Bragado, P. (2020). Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 26(6), 1432\u20131448. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0353","DOI":"10.1158\/1078-0432.CCR-19-0353"},{"key":"10353_CR71","doi-asserted-by":"publisher","unstructured":"Oudard, S., Culine, S., Vano, Y., Goldwasser, F., Th\u00e9odore, C., Nguyen, T., \u2026 & Beuzeboc, P. (2015). Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. European Journal of Cancer, 51(1), 45\u201354. https:\/\/doi.org\/10.1016\/j.ejca.2014.10.009","DOI":"10.1016\/j.ejca.2014.10.009"},{"key":"10353_CR72","doi-asserted-by":"publisher","unstructured":"Dahl, D. M., Karrison, T. G., Michaelson, M. D., Pham, H. T., Wu, C.-L., Swanson, G. P., \u2026 & Efstathiou, J. A. (2024). Long-term outcomes of chemoradiation for muscle-invasive bladder cancer in noncystectomy candidates. Final results of NRG oncology RTOG 0524-a phase 1\/2 trial of paclitaxel\u00a0+\u00a0trastuzumab with daily radiation or paclitaxel alone with daily irradiation. European Urology Oncology, 7(1), 83\u201390. https:\/\/doi.org\/10.1016\/j.euo.2023.05.013","DOI":"10.1016\/j.euo.2023.05.013"},{"key":"10353_CR73","doi-asserted-by":"publisher","unstructured":"Connolly, R. M., Wang, V., Hyman, D. M., Grivas, P., Mitchell, E. P., Wright, J. J., \u2026 & Flaherty, K. T. (2024). Trastuzumab and pertuzumab in patients with non-breast\/gastroesophageal HER2 -amplified tumors: Results from the NCI\u2013MATCH ECOG\u2013ACRIN trial (EAY131) subprotocol J. Clinical Cancer Research, 30(7), 1273\u20131280. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0633","DOI":"10.1158\/1078-0432.CCR-23-0633"},{"key":"10353_CR74","doi-asserted-by":"publisher","unstructured":"Sweeney, C. J., Hainsworth, J. D., Bose, R., Burris, H. A., Kurzrock, R., Swanton, C., \u2026 & Meric-Bernstam, F. (2024). MyPathway human epidermal growth factor receptor 2 basket study: Pertuzumab + trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2\u2013altered advanced solid tumors. Journal of Clinical Oncology, 42(3), 258\u2013265. https:\/\/doi.org\/10.1200\/JCO.22.02636","DOI":"10.1200\/JCO.22.02636"},{"key":"10353_CR75","doi-asserted-by":"publisher","unstructured":"Meric-Bernstam, F., Beeram, M., Hamilton, E., Oh, D.-Y., Hanna, D. L., Kang, Y.-K., \u2026 & Lee, K.-W. (2022). Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: A phase 1, dose-escalation and expansion study. The Lancet Oncology, 23(12), 1558\u20131570. https:\/\/doi.org\/10.1016\/S1470-2045(22)00621-0","DOI":"10.1016\/S1470-2045(22)00621-0"},{"key":"10353_CR76","doi-asserted-by":"publisher","unstructured":"Kim, M., Lee, J. L., Shin, S. J., Bae, W. K., Lee, H. J., Byun, J. H., \u2026 & Keam, B. (2023). Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18\u201318. ESMO open, 8(4), 101588. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101588","DOI":"10.1016\/j.esmoop.2023.101588"},{"key":"10353_CR77","doi-asserted-by":"publisher","unstructured":"Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., \u2026 & Solit, D. B. (2018). HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 554(7691), 189\u2013194. https:\/\/doi.org\/10.1038\/nature25475","DOI":"10.1038\/nature25475"},{"key":"10353_CR78","doi-asserted-by":"publisher","unstructured":"W\u00fclfing, C., Machiels, J. H., Richel, D. J., Grimm, M., Treiber, U., De Groot, M. R., \u2026 & El\u2010Hariry, I. A. (2009). A single\u2010arm, multicenter, open\u2010label phase 2 study of lapatinib as the second\u2010line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer, 115(13), 2881\u20132890. https:\/\/doi.org\/10.1002\/cncr.24337","DOI":"10.1002\/cncr.24337"},{"key":"10353_CR79","doi-asserted-by":"publisher","unstructured":"Galsky, M. D., Von Hoff, D. D., Neubauer, M., Anderson, T., Fleming, M., Nagarwala, Y., \u2026 & Zaks, T. Z. (2012). Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Investigational New Drugs, 30(2), 695\u2013701. https:\/\/doi.org\/10.1007\/s10637-010-9541-0","DOI":"10.1007\/s10637-010-9541-0"},{"issue":"3","key":"10353_CR80","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.4143\/crt.2015.405","volume":"48","author":"V Narayan","year":"2016","unstructured":"Narayan, V., Mamtani, R., Keefe, S., Guzzo, T., Malkowicz, S. B., & Vaughn, D. J. (2016). Cisplatin, gemcitabine, and lapatinib as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer Research and Treatment, 48(3), 1084\u20131091. https:\/\/doi.org\/10.4143\/crt.2015.405","journal-title":"Cancer Research and Treatment"},{"key":"10353_CR81","doi-asserted-by":"publisher","unstructured":"Cerbone, L., Sternberg, C. N., Sengel\u00f8v, L., Agerbaek, M., Van Herpen, C., Marreaud, S., \u2026 & Daugaard, G. (2016). Results from a phase I study of lapatinib with gemcitabine and cisplatin in advanced or metastatic bladder cancer: EORTC trial 30061. Oncology, 90(1), 21\u201328. https:\/\/doi.org\/10.1159\/000440959","DOI":"10.1159\/000440959"},{"key":"10353_CR82","doi-asserted-by":"publisher","unstructured":"Tang, S., Dorff, T. B., Tsao-Wei, D. D., Massopust, K., Ketchens, C., Hu, J., \u2026 & Quinn, D. I. (2016). Single arm phase II study of docetaxel and lapatinib in metastatic urothelial cancer: USC trial 4B-10\u20134. Journal of Clinical Oncology, 34(2_suppl), 424\u2013424. https:\/\/doi.org\/10.1200\/jco.2016.34.2_suppl.424","DOI":"10.1200\/jco.2016.34.2_suppl.424"},{"key":"10353_CR83","doi-asserted-by":"publisher","unstructured":"Powles, T., Huddart, R. A., Elliott, T., Sarker, S.-J., Ackerman, C., Jones, R., \u2026 & Chowdhury, S. (2017). Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2\u2013positive metastatic bladder cancer. Journal of Clinical Oncology, 35(1), 48\u201355. https:\/\/doi.org\/10.1200\/JCO.2015.66.3468","DOI":"10.1200\/JCO.2015.66.3468"},{"key":"10353_CR84","doi-asserted-by":"publisher","unstructured":"Kwak, E. L., Shapiro, G. I., Cohen, S. M., Becerra, C. R., Lenz, H.-J., Cheng, W.-F., \u2026 & Iafrate, A. J. (2013). Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Cancer, 119(16), 3043\u20133051. https:\/\/doi.org\/10.1002\/cncr.28120","DOI":"10.1002\/cncr.28120"},{"key":"10353_CR85","doi-asserted-by":"publisher","unstructured":"Choudhury, N. J., Campanile, A., Antic, T., Yap, K. L., Fitzpatrick, C. A., Wade, J. L., \u2026 & O\u2019Donnell, P. H. (2016). Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. Journal of Clinical Oncology, 34(18), 2165\u20132171. https:\/\/doi.org\/10.1200\/JCO.2015.66.3047","DOI":"10.1200\/JCO.2015.66.3047"},{"key":"10353_CR86","doi-asserted-by":"publisher","unstructured":"Bedard, P. L., Li, S., Wisinski, K. B., Yang, E. S., Limaye, S. A., Mitchell, E. P., \u2026 & Flaherty, K. T. (2022). Phase II study of afatinib in patients with tumors with human epidermal growth factor receptor 2-activating mutations: Results from the national cancer institute-molecular analysis for therapy choice ECOG-ACRIN trial (EAY131) subprotocol EAY131-B. JCO precision oncology, 6, e2200165. https:\/\/doi.org\/10.1200\/PO.22.00165","DOI":"10.1200\/PO.22.00165"},{"key":"10353_CR87","doi-asserted-by":"publisher","unstructured":"Font, A., Mellado, B., Climent, M. A., Virizuela, J. A., Oudard, S., Puente, J., \u2026 & Real, F. X. (2024). Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1\u20133 (LUX-bladder 1). British Journal of Cancer, 130(3), 434\u2013441. https:\/\/doi.org\/10.1038\/s41416-023-02513-6","DOI":"10.1038\/s41416-023-02513-6"},{"key":"10353_CR88","doi-asserted-by":"publisher","unstructured":"Galsky, M. D., Del Conte, G., Foti, S., Yu, E. Y., Machiels, J.-P. H., Doger, B., \u2026 & L\u00fcftner, D. (2022). Primary analysis from DS8201-a-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). Journal of Clinical Oncology, 40(6_suppl), 438\u2013438. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.438","DOI":"10.1200\/JCO.2022.40.6_suppl.438"},{"key":"10353_CR89","doi-asserted-by":"publisher","unstructured":"Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D.-Y., Banerjee, S., Gonz\u00e1lez-Mart\u00edn, A., \u2026 & Lee, J.-Y. (2024). Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. Journal of Clinical Oncology, 42(1), 47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005","DOI":"10.1200\/JCO.23.02005"},{"key":"10353_CR90","doi-asserted-by":"publisher","unstructured":"Hamilton, E., Galsky, M. D., Ochsenreither, S., Del Conte, G., Mart\u00edn, M., De Miguel, M. J., \u2026 & Hurvitz, S. (2024). Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: Analysis of the phase ib DS8201-a-U105 study. Clinical Cancer Research, 30(24), 5548\u20135558. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1513","DOI":"10.1158\/1078-0432.CCR-24-1513"},{"key":"10353_CR91","doi-asserted-by":"publisher","unstructured":"De Vries, E. G. E., R\u00fcschoff, J., Lolkema, M., Tabernero, J., Gianni, L., Voest, E., \u2026 & Viale, G. (2023). Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma. Cancer Medicine, 12(11), 12071\u201312083. https:\/\/doi.org\/10.1002\/cam4.5893","DOI":"10.1002\/cam4.5893"},{"key":"10353_CR92","doi-asserted-by":"publisher","unstructured":"Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., \u2026 & Aftimos, P. (2019). Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study. The Lancet. Oncology, 20(8), 1124\u20131135. https:\/\/doi.org\/10.1016\/S1470-2045(19)30328-6","DOI":"10.1016\/S1470-2045(19)30328-6"},{"key":"10353_CR93","doi-asserted-by":"publisher","unstructured":"Xu, Y., Wang, Y., Gong, J., Zhang, X., Peng, Z., Sheng, X., \u2026 & Shen, L. (2021). Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 24(4), 913\u2013925. https:\/\/doi.org\/10.1007\/s10120-021-01168-7","DOI":"10.1007\/s10120-021-01168-7"},{"key":"10353_CR94","doi-asserted-by":"publisher","unstructured":"Xu, H., Sheng, X., Yan, X., Chi, Z., Cui, C., Si, L., \u2026 & Guo, J. (2020). A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma. Journal of Clinical Oncology, 38(15_suppl), e17113\u2013e17113. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e17113","DOI":"10.1200\/JCO.2020.38.15_suppl.e17113"},{"key":"10353_CR95","doi-asserted-by":"publisher","unstructured":"Sheng, X., Wang, L., He, Z., Shi, Y., Luo, H., Han, W., \u2026 & Guo, J. (2024). Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2\u2013positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials. Journal of Clinical Oncology, 42(12), 1391\u20131402. https:\/\/doi.org\/10.1200\/JCO.22.02912","DOI":"10.1200\/JCO.22.02912"},{"key":"10353_CR96","doi-asserted-by":"publisher","unstructured":"Galsky, M. D., Koshkin, V. S., Campbell, M. T., Drakaki, A., Bowman, I., Rose, A. A. N., \u2026 & Powles, T. B. (2024). 1967MO preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la\/mUC): RC48G001 cohort C. Annals of Oncology, 35, S1138\u2013S1139. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2052","DOI":"10.1016\/j.annonc.2024.08.2052"},{"key":"10353_CR97","doi-asserted-by":"publisher","unstructured":"Sheng, X., Zeng, G., Zhang, C., Zhang, Q., Bian, J., Niu, H., \u2026 & Guo, J. (2025). Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer. New England Journal of Medicine, 393(23), 2324\u20132337. https:\/\/doi.org\/10.1056\/NEJMoa2511648","DOI":"10.1056\/NEJMoa2511648"},{"key":"10353_CR98","doi-asserted-by":"publisher","unstructured":"Sheng, X., Zhang, C., Ji, Y., Zhou, L., Zou, B., Huang, H., \u2026 & Guo, J. (2025). Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. Journal of Clinical Oncology, 43(5_suppl), 665\u2013665. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.665","DOI":"10.1200\/JCO.2025.43.5_suppl.665"},{"key":"10353_CR99","doi-asserted-by":"publisher","unstructured":"Qu, W., Fu, C., Han, W., Luo, H., Quan, J., Chen, L., \u2026 & Zhou, A. (2024). A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma. European Journal of Cancer, 205, 114096. https:\/\/doi.org\/10.1016\/j.ejca.2024.114096","DOI":"10.1016\/j.ejca.2024.114096"},{"key":"10353_CR100","doi-asserted-by":"publisher","unstructured":"Bajorin, D. F., Sharma, P., Quinn, D. I., Plimack, E. R., Hoffman-Censits, J. H., O\u2019Donnell, P. H., \u2026 & Gomella, L. G. (2016). Phase 2 trial results of DN24\u201302, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts). Journal of Clinical Oncology, 34(15_suppl), 4513\u20134513. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.4513","DOI":"10.1200\/JCO.2016.34.15_suppl.4513"},{"key":"10353_CR101","doi-asserted-by":"publisher","unstructured":"Maeng, H. M., Moore, B. N., Bagheri, H., Steinberg, S. M., Inglefield, J., Dunham, K., \u2026 & Berzofsky, J. A. (2021). Phase I clinical trial of an autologous dendritic cell vaccine against HER2 shows safety and preliminary clinical efficacy. Frontiers in Oncology, 11, 789078. https:\/\/doi.org\/10.3389\/fonc.2021.789078","DOI":"10.3389\/fonc.2021.789078"},{"key":"10353_CR102","doi-asserted-by":"publisher","unstructured":"Qu, M., Zhou, L., Yan, X., Li, S., Wu, X., Xu, H., \u2026 & Sheng, X. (2023). Advances in HER2-targeted treatment for advanced\/metastatic urothelial carcinoma. Bladder, 10(1), 1. https:\/\/doi.org\/10.14440\/bladder.2023.871","DOI":"10.14440\/bladder.2023.871"},{"key":"10353_CR103","doi-asserted-by":"publisher","unstructured":"Michaelson, M. D., Hu, C., Pham, H. T., Dahl, D. M., Lee-Wu, C., Swanson, G. P., \u2026 & Shipley, W. (2017). A phase 1\/2 trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation after transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer (trial NRG oncology RTOG 0524). International Journal of Radiation Oncology*Biology*Physics, 97(5), 995\u20131001. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.12.018","DOI":"10.1016\/j.ijrobp.2016.12.018"},{"key":"10353_CR104","doi-asserted-by":"publisher","unstructured":"Hussain, M. H. A., MacVicar, G. R., Petrylak, D. P., Dunn, R. L., Vaishampayan, U., Lara, P. N., \u2026 & Smith, D. C. (2007). Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/ neu \u2013positive urothelial carcinoma: Results of a multicenter phase II national cancer institute trial. Journal of Clinical Oncology, 25(16), 2218\u20132224. https:\/\/doi.org\/10.1200\/JCO.2006.08.0994","DOI":"10.1200\/JCO.2006.08.0994"},{"key":"10353_CR105","doi-asserted-by":"publisher","unstructured":"Ikeda, S., Kudo, R., Yamashita, Y., Kubo, T., Mori, Y., Harada, Y., \u2026 & Toyooka, S. (2022). Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors. Journal of Clinical Oncology, 40(16_suppl), 3131\u20133131. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.3131","DOI":"10.1200\/JCO.2022.40.16_suppl.3131"},{"key":"10353_CR106","doi-asserted-by":"publisher","unstructured":"Kriajevska. (2009). Lapatinib, a dual inhibitor of ErbB-1\/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. International Journal of Oncology, 34(4). https:\/\/doi.org\/10.3892\/ijo_00000244","DOI":"10.3892\/ijo_00000244"},{"key":"10353_CR107","doi-asserted-by":"publisher","unstructured":"Kulukian, A., Lee, P., Taylor, J., Rosler, R., De Vries, P., Watson, D., \u2026 & Peterson, S. (2020). Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Molecular Cancer Therapeutics, 19(4), 976\u2013987. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0873","DOI":"10.1158\/1535-7163.MCT-19-0873"},{"key":"10353_CR108","doi-asserted-by":"publisher","unstructured":"Grivas, P. D., Day, K. C., Karatsinides, A., Paul, A., Shakir, N., Owainati, I., \u2026 & Day, M. L. (2013). Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer. Molecular Medicine, 19(1), 367\u2013376. https:\/\/doi.org\/10.2119\/molmed.2013.00108","DOI":"10.2119\/molmed.2013.00108"},{"issue":"12","key":"10353_CR109","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","volume":"25","author":"A Zippelius","year":"2025","unstructured":"Zippelius, A., Tolaney, S. M., Tarantino, P., Balthasar, J. P., & Thurber, G. M. (2025). Unveiling the molecular and immunological drivers of antibody\u2013drug conjugates in cancer treatment. Nature Reviews Cancer, 25(12), 925\u2013944. https:\/\/doi.org\/10.1038\/s41568-025-00869-w","journal-title":"Nature Reviews Cancer"},{"issue":"10","key":"10353_CR110","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang, Z., Li, H., Gou, L., Li, W., & Wang, Y. (2023). Antibody\u2013drug conjugates: Recent advances in payloads. Acta Pharmaceutica Sinica B, 13(10), 4025\u20134059. https:\/\/doi.org\/10.1016\/j.apsb.2023.06.015","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10353_CR111","doi-asserted-by":"publisher","unstructured":"Guo, Y., Shen, Z., Zhao, W., Lu, J., Song, Y., Shen, L., \u2026 & Dong, X. (2024). Rational identification of novel antibody\u2010drug conjugate with high bystander killing effect against heterogeneous tumors. Advanced Science, 11(13), 2306309. https:\/\/doi.org\/10.1002\/advs.202306309","DOI":"10.1002\/advs.202306309"},{"issue":"1","key":"10353_CR112","doi-asserted-by":"publisher","first-page":"2533488","DOI":"10.1080\/2162402X.2025.2533488","volume":"14","author":"O Kepp","year":"2025","unstructured":"Kepp, O., & Kroemer, G. (2025). Immunogenic cell death and bystander killing: Expanding the therapeutic potential of modern antibody-drug conjugates. OncoImmunology, 14(1), 2533488. https:\/\/doi.org\/10.1080\/2162402X.2025.2533488","journal-title":"OncoImmunology"},{"key":"10353_CR113","doi-asserted-by":"publisher","unstructured":"Von Arx, C., De Placido, P., Caltavituro, A., Di Rienzo, R., Buonaiuto, R., De Laurentiis, M., \u2026 & Del Mastro, L. (2023). The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treatment Reviews, 113, 102500. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102500","DOI":"10.1016\/j.ctrv.2022.102500"},{"key":"10353_CR114","doi-asserted-by":"publisher","unstructured":"Hayashi, T., Seiler, R., Oo, H. Z., J\u00e4ger, W., Moskalev, I., Awrey, S., \u2026 & Black, P. C. (2015). Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer. Journal of Urology, 194(4), 1120\u20131131. https:\/\/doi.org\/10.1016\/j.juro.2015.05.087","DOI":"10.1016\/j.juro.2015.05.087"},{"key":"10353_CR115","doi-asserted-by":"publisher","unstructured":"Liu, D., Makker, V., Buonocore, D. J., Shen, R., Yaeger, R., Ginsberg, M. S., \u2026 & Li, B. T. (2023). Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers. Journal of Clinical Oncology, 41(16_suppl), 3025\u20133025. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3025","DOI":"10.1200\/JCO.2023.41.16_suppl.3025"},{"key":"10353_CR116","doi-asserted-by":"publisher","unstructured":"Cort\u00e9s, J., Hurvitz, S. A., Im, S.-A., Iwata, H., Curigliano, G., Kim, S.-B., \u2026 & Hamilton, E. (2024). Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial. Nature Medicine, 30(8), 2208\u20132215. https:\/\/doi.org\/10.1038\/s41591-024-03021-7","DOI":"10.1038\/s41591-024-03021-7"},{"issue":"1","key":"10353_CR117","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","volume":"29","author":"F Shi","year":"2022","unstructured":"Shi, F., Liu, Y., Zhou, X., Shen, P., Xue, R., & Zhang, M. (2022). Disitamab vedotin: A novel antibody-drug conjugates for cancer therapy. Drug Delivery, 29(1), 1335\u20131344. https:\/\/doi.org\/10.1080\/10717544.2022.2069883","journal-title":"Drug Delivery"},{"issue":"5","key":"10353_CR118","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu, Y., Wang, Z., & Wang, Y. (2024). Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharmaceutica Sinica B, 14(5), 1965\u20131986. https:\/\/doi.org\/10.1016\/j.apsb.2024.01.009","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"2","key":"10353_CR119","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10637-025-01507-w","volume":"43","author":"H Huang","year":"2025","unstructured":"Huang, H., Zhou, Y., Shang, C., Zhang, Y., & Shen, Y. (2025). A novel anti-HER2\/EGFR bispecific antibody\u2013drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs. Investigational New Drugs, 43(2), 262\u2013275. https:\/\/doi.org\/10.1007\/s10637-025-01507-w","journal-title":"Investigational New Drugs"},{"key":"10353_CR120","doi-asserted-by":"publisher","unstructured":"Zong, H., Li, X., Han, L., Wang, L., Liu, J., Yue, Y., \u2026 & Zhu, J. (2024). A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer. Acta Pharmacologica Sinica, 45(8), 1727\u20131739. https:\/\/doi.org\/10.1038\/s41401-024-01279-8","DOI":"10.1038\/s41401-024-01279-8"},{"key":"10353_CR121","doi-asserted-by":"publisher","unstructured":"Andreev, J., Thambi, N., Perez Bay, A. E., Delfino, F., Martin, J., Kelly, M. P., \u2026 & Thurston, G. (2017). Bispecific antibodies and antibody\u2013drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Molecular Cancer Therapeutics, 16(4), 681\u2013693. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0658","DOI":"10.1158\/1535-7163.MCT-16-0658"},{"key":"10353_CR122","doi-asserted-by":"publisher","unstructured":"Zhong, H., Xiong, Y., Huang, H., Pan, Y., Cao, L., Liu, S., \u2026 & Bao, H. (2023). Preclinical antitumor activity of an anti-HER2\/trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor. Journal of Clinical Oncology, 41(16_suppl), e15013\u2013e15013. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e15013","DOI":"10.1200\/JCO.2023.41.16_suppl.e15013"},{"key":"10353_CR123","doi-asserted-by":"publisher","unstructured":"Patelli, G., Zeppellini, A., Spina, F., Righetti, E., Stabile, S., Amatu, A., \u2026 & Sartore-Bianchi, A. (2022). The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. Cancer Treatment Reviews, 104, 102351. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102351","DOI":"10.1016\/j.ctrv.2022.102351"},{"key":"10353_CR124","doi-asserted-by":"publisher","unstructured":"Al-Hawary, S. I. S., Saleh, E. A. M., Mamajanov, N. A., S. Gilmanova, N., Alsaab, H. O., Alghamdi, A., \u2026 & Ibrahim, A. J. (2023). Breast cancer vaccines; a comprehensive and updated review. Pathology - Research and Practice, 249, 154735. https:\/\/doi.org\/10.1016\/j.prp.2023.154735","DOI":"10.1016\/j.prp.2023.154735"},{"key":"10353_CR125","doi-asserted-by":"publisher","unstructured":"Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., \u2026 & Gill, S. (2020). Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology, 38(8), 947\u2013953. https:\/\/doi.org\/10.1038\/s41587-020-0462-y","DOI":"10.1038\/s41587-020-0462-y"},{"key":"10353_CR126","doi-asserted-by":"publisher","unstructured":"Reiss, K. A., Angelos, M. G., Dees, E. C., Yuan, Y., Ueno, N. T., Pohlmann, P. R., \u2026 & Abdou, Y. (2025). CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: A phase 1 trial. Nature Medicine, 31(4), 1171\u20131182. https:\/\/doi.org\/10.1038\/s41591-025-03495-z","DOI":"10.1038\/s41591-025-03495-z"},{"issue":"6","key":"10353_CR127","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41571-025-01016-y","volume":"22","author":"CJ Robbins","year":"2025","unstructured":"Robbins, C. J., Bates, K. M., & Rimm, D. L. (2025). HER2 testing: Evolution and update for a companion diagnostic assay. Nature Reviews. Clinical Oncology, 22(6), 408\u2013423. https:\/\/doi.org\/10.1038\/s41571-025-01016-y","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10353_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.676939","volume":"11","author":"JT J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen, J. T., Winther, H., Askaa, J., Andresen, L., Olsen, D., & Mollerup, J. (2021). A companion diagnostic with significant clinical impact in treatment of breast and gastric cancer. Frontiers in Oncology, 11, Article 676939. https:\/\/doi.org\/10.3389\/fonc.2021.676939","journal-title":"Frontiers in Oncology"},{"key":"10353_CR129","doi-asserted-by":"publisher","unstructured":"O\u2019Grady, A., Allen, D., Happerfield, L., Johnson, N., Provenzano, E., Pinder, S. E., \u2026 & Kay, E. W. (2010). An immunohistochemical and fluorescence in situ hybridization-based comparison between the oracle HER2 bond immunohistochemical system, dako HercepTest, and vysis PathVysion HER2 FISH using both commercially validated and modified ASCO\/CAP and united kingdom HER2 IHC scoring guidelines. Applied Immunohistochemistry & Molecular morphology: AIMM, 18(6), 489\u2013493. https:\/\/doi.org\/10.1097\/PAI.0b013e3181e3d893","DOI":"10.1097\/PAI.0b013e3181e3d893"},{"key":"10353_CR130","doi-asserted-by":"publisher","unstructured":"Cappellesso, R., Fassan, M., Hanspeter, E., Bornschein, J., d\u2019Amore, E. S. G., Cuorvo, L. V., \u2026 & Rugge, M. (2015). HER2 status in gastroesophageal cancer: A tissue microarray study of 1040 cases. Human Pathology, 46(5), 665\u2013672. https:\/\/doi.org\/10.1016\/j.humpath.2015.02.007","DOI":"10.1016\/j.humpath.2015.02.007"},{"issue":"8","key":"10353_CR131","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nbt0806-914","volume":"24","author":"DL Rimm","year":"2006","unstructured":"Rimm, D. L. (2006). What brown cannot do for you. Nature Biotechnology, 24(8), 914\u2013916. https:\/\/doi.org\/10.1038\/nbt0806-914","journal-title":"Nature Biotechnology"},{"key":"10353_CR132","doi-asserted-by":"publisher","unstructured":"Laokulrath, N., Gudi, M., Salahuddin, S. A., Chong, A. P. Y., Ding, C., Iqbal, J., \u2026 & Tan, P. H. (2024). Human epidermal growth factor receptor 2 (HER2) status in breast cancer: Practice points and challenges. Histopathology, 85(3), 371\u2013382. https:\/\/doi.org\/10.1111\/his.15213","DOI":"10.1111\/his.15213"},{"key":"10353_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102826","volume":"130","author":"X Liu","year":"2024","unstructured":"Liu, X., Song, Y., Cheng, P., Liang, B., & Xing, D. (2024). Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes. Cancer Treatment Reviews, 130, Article 102826. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102826","journal-title":"Cancer Treatment Reviews"},{"key":"10353_CR134","doi-asserted-by":"publisher","unstructured":"Robbins, C. J., Fernandez, A. I., Han, G., Wong, S., Harigopal, M., Podoll, M., \u2026 & Rimm, D. L. (2023). Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 36(1), 100032. https:\/\/doi.org\/10.1016\/j.modpat.2022.100032","DOI":"10.1016\/j.modpat.2022.100032"},{"key":"10353_CR135","doi-asserted-by":"publisher","unstructured":"Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., \u2026 & College of American Pathologists. (2007). American society of clinical oncology\/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 25(1), 118\u2013145. https:\/\/doi.org\/10.1200\/JCO.2006.09.2775","DOI":"10.1200\/JCO.2006.09.2775"},{"key":"10353_CR136","doi-asserted-by":"publisher","unstructured":"Kiyose, S., Igarashi, H., Nagura, K., Kamo, T., Kawane, K., Mori, H., \u2026 & Sugimura, H. (2012). Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: Comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Pathology International, 62(11), 728\u2013734. https:\/\/doi.org\/10.1111\/j.1440-1827.2012.02862.x","DOI":"10.1111\/j.1440-1827.2012.02862.x"},{"issue":"8","key":"10353_CR137","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105961","volume":"9","author":"Z Varga","year":"2014","unstructured":"Varga, Z., Tubbs, R. R., & Moch, H. (2014). Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification. PLoS ONE, 9(8), Article e105961. https:\/\/doi.org\/10.1371\/journal.pone.0105961","journal-title":"PLoS ONE"},{"key":"10353_CR138","doi-asserted-by":"publisher","unstructured":"Hwang, C.-C., Pintye, M., Chang, L.-C., Chen, H.-Y., Yeh, K.-Y., Chein, H.-P., \u2026 & Chen, J.-R. (2011). Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing. Histopathology, 59(5), 984\u2013992. https:\/\/doi.org\/10.1111\/j.1365-2559.2011.04037.x","DOI":"10.1111\/j.1365-2559.2011.04037.x"},{"key":"10353_CR139","doi-asserted-by":"publisher","unstructured":"Ross, J. S., Wang, K., Gay, L. M., Al-Rohil, R. N., Nazeer, T., Sheehan, C. E., \u2026 & Stephens, P. J. (2014). A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 20(1), 68\u201375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1992","DOI":"10.1158\/1078-0432.CCR-13-1992"},{"key":"10353_CR140","doi-asserted-by":"publisher","unstructured":"Tian, P., Zeng, H., Ji, L., Ding, Z., Ren, L., Gao, W., \u2026 & Li, W. (2021). Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy. Lung Cancer, 160, 50\u201358. https:\/\/doi.org\/10.1016\/j.lungcan.2021.07.014","DOI":"10.1016\/j.lungcan.2021.07.014"},{"key":"10353_CR141","doi-asserted-by":"publisher","unstructured":"Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., \u2026 & Yelensky, R. (2013). Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 31(11), 1023\u20131031. https:\/\/doi.org\/10.1038\/nbt.2696","DOI":"10.1038\/nbt.2696"},{"key":"10353_CR142","doi-asserted-by":"publisher","unstructured":"Wolff, A. C., Somerfield, M. R., Dowsett, M., Hammond, M. E. H., Hayes, D. F., McShane, L. M., \u2026 & Allison, K. H. (2023). Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013college of American pathologists guideline update. Journal of Clinical Oncology, 41(22), 3867\u20133872. https:\/\/doi.org\/10.1200\/JCO.22.02864","DOI":"10.1200\/JCO.22.02864"},{"key":"10353_CR143","doi-asserted-by":"publisher","unstructured":"Bartley, A. N., Washington, M. K., Colasacco, C., Ventura, C. B., Ismaila, N., Benson, A. B., \u2026 & Ajani, J. A. (2017). HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American pathologists, American society for clinical pathology, and the American society of clinical oncology. Journal of Clinical Oncology, 35(4), 446\u2013464. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836","DOI":"10.1200\/JCO.2016.69.4836"},{"key":"10353_CR144","doi-asserted-by":"publisher","unstructured":"Wang, F.-H., Zhang, X.-T., Tang, L., Wu, Q., Cai, M.-Y., Li, Y.-F., \u2026 & Xu, R.-H. (2024). The Chinese society of clinical oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Communications, 44(1), 127\u2013172. https:\/\/doi.org\/10.1002\/cac2.12516","DOI":"10.1002\/cac2.12516"},{"key":"10353_CR145","doi-asserted-by":"publisher","unstructured":"Ajani, J. A., D\u2019Amico, T. A., Bentrem, D. J., Chao, J., Cooke, D., Corvera, C., \u2026 & Pluchino, L. A. (2022). Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 20(2), 167\u2013192. https:\/\/doi.org\/10.6004\/jnccn.2022.0008","DOI":"10.6004\/jnccn.2022.0008"},{"issue":"1","key":"10353_CR146","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3760\/cma.j.cn112151-20251009-00668","volume":"55","author":"Members of Urothelial Carcinoma Expert Panel on Clinical Pathological Expert Consensus on HER2 Immunohistochemical Testing in Urothelial Carcinoma (2026 version)","year":"2026","unstructured":"Members of Urothelial Carcinoma Expert Panel on Clinical Pathological Expert Consensus on HER2 Immunohistochemical Testing in Urothelial Carcinoma (2026 version). (2026). clinical pathological expert consensus on HER2 immunohistochemical testing in urothelial carcinoma(2026 version). Zhonghua Bing Li Xue Za Zhi [Chinese Journal of Pathology], 55(1), 7\u201315. https:\/\/doi.org\/10.3760\/cma.j.cn112151-20251009-00668","journal-title":"Zhonghua Bing Li Xue Za Zhi [Chinese Journal of Pathology]"},{"key":"10353_CR147","doi-asserted-by":"publisher","unstructured":"Shipp, C. A., Jindal, T., Reyes, K. R., Zhu, X., Ding, C.-K. C., Chan, E., \u2026 & Koshkin, V. S. (2024). Association of HER2 expression in advanced urothelial carcinoma (aUC) and treatment outcomes with immune checkpoint inhibitors and enfortumab vedotin. Journal of Clinical Oncology, 42(4_suppl), 599\u2013599. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.599","DOI":"10.1200\/JCO.2024.42.4_suppl.599"},{"issue":"2","key":"10353_CR148","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/00365599.2011.637955","volume":"46","author":"H Olsson","year":"2012","unstructured":"Olsson, H., Fyhr, I.-M., Hultman, P., & Jahnson, S. (2012). HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scandinavian Journal of Urology and Nephrology, 46(2), 102\u2013107. https:\/\/doi.org\/10.3109\/00365599.2011.637955","journal-title":"Scandinavian Journal of Urology and Nephrology"},{"issue":"3","key":"10353_CR149","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.euf.2016.06.007","volume":"4","author":"K Behzato\u011flu","year":"2018","unstructured":"Behzato\u011flu, K., Y\u00f6r\u00fcko\u011flu, K., Demir, H., & Bal, N. (2018). Human epidermal growth factor receptor 2 overexpression in micropapillary and other variants of urothelial carcinoma. European Urology Focus, 4(3), 399\u2013404. https:\/\/doi.org\/10.1016\/j.euf.2016.06.007","journal-title":"European Urology Focus"},{"key":"10353_CR150","doi-asserted-by":"publisher","unstructured":"Li, K. M., Liu, M. L., Wu, S. F., Hong, R. P., Liu, Y. Y., Zeng, L. L., \u2026 & Zeng, X. (2025). [association between HER2 overexpression and recurrence rate in patients with non-muscle-invasive bladder cancer following anthracycline-based intravesical instillation therapy]. Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 54(11), 1193\u20131198. https:\/\/doi.org\/10.3760\/cma.j.cn112151-20250208-00082","DOI":"10.3760\/cma.j.cn112151-20250208-00082"},{"key":"10353_CR151","doi-asserted-by":"publisher","unstructured":"Sheng, X., Yan, X., Wang, L., Shi, Y., Yao, X., Luo, H., \u2026 & Guo, J. (2021). Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody\u2013drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clinical Cancer Research, 27(1), 43\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2488","DOI":"10.1158\/1078-0432.CCR-20-2488"},{"key":"10353_CR152","doi-asserted-by":"publisher","unstructured":"Ye, J., Chen, Z., Liao, X., Wang, X., Zhang, C., Han, P., \u2026 & Bao, Y. (2024). HER2 expression in upper tract urothelial carcinoma and the relationship with clinicopathological characteristics-an analysis of 155 patients in southwest China. World Journal of Urology, 42(1), 521. https:\/\/doi.org\/10.1007\/s00345-024-05222-8","DOI":"10.1007\/s00345-024-05222-8"},{"key":"10353_CR153","doi-asserted-by":"publisher","unstructured":"Zhou, L., Shao, Z., Liu, Y., Yan, X., Li, J., Wu, X., \u2026 & Sheng, X. (2023). HER2 expression associated with clinical characteristics and prognosis of urothelial carcinoma in a Chinese population. The Oncologist, 28(8), e617\u2013e624. https:\/\/doi.org\/10.1093\/oncolo\/oyad070","DOI":"10.1093\/oncolo\/oyad070"},{"key":"10353_CR154","doi-asserted-by":"publisher","unstructured":"Zou, S., Liu, Z., Zhou, J., Song, S., Wang, D., Zhu, D., \u2026 & Zhu, X. (2025). Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]ga-HER2 affibody PET\/CT imaging: Preliminary clinical findings. European Journal of Nuclear Medicine and Molecular Imaging, 52(8), 2782\u20132791. https:\/\/doi.org\/10.1007\/s00259-025-07142-0","DOI":"10.1007\/s00259-025-07142-0"},{"key":"10353_CR155","doi-asserted-by":"publisher","unstructured":"Moktefi, A., Pouessel, D., Liu, J., Sirab, N., Maille, P., Soyeux, P., \u2026 & Allory, Y. (2018). Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. Modern Pathology, 31(8), 1270\u20131281. https:\/\/doi.org\/10.1038\/s41379-018-0023-9","DOI":"10.1038\/s41379-018-0023-9"},{"key":"10353_CR156","doi-asserted-by":"publisher","unstructured":"Mohanty, S. K., Mishra, S. K., Tiwari, A., Sharma, S., Bhardwaj, M., Pattnaik, N., \u2026 & Parwani, A. V. (2021). Reappraisal of HER2 amplification in high-grade urothelial carcinoma based on 2018 ASCO\/CAP clinical practice guidelines. American Journal of Clinical Pathology, 156(6), 1130\u20131141. https:\/\/doi.org\/10.1093\/ajcp\/aqab083","DOI":"10.1093\/ajcp\/aqab083"},{"key":"10353_CR157","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","volume":"72","author":"C Marchi\u00f2","year":"2021","unstructured":"Marchi\u00f2, C., Annaratone, L., Marques, A., Casorzo, L., Berrino, E., & Sapino, A. (2021). Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Seminars in Cancer Biology, 72, 123\u2013135. https:\/\/doi.org\/10.1016\/j.semcancer.2020.02.016","journal-title":"Seminars in Cancer Biology"},{"key":"10353_CR158","doi-asserted-by":"publisher","unstructured":"Lim, S. D., Cho, Y. M., Choi, G.-S., Park, H. K., Paick, S. H., Kim, W. Y., \u2026 & Yoon, G. (2015). Clinical significance of substaging and HER2 expression in papillary nonmuscle invasive urothelial cancers of the urinary bladder. Journal of Korean Medical Science, 30(8), 1068\u20131077. https:\/\/doi.org\/10.3346\/jkms.2015.30.8.1068","DOI":"10.3346\/jkms.2015.30.8.1068"},{"key":"10353_CR159","doi-asserted-by":"publisher","unstructured":"Tan, X., Liu, Z., Cai, T., Wang, Y., Wu, Z., Qin, Z., \u2026 & Yao, K. (2024). Prognostic significance of HER2 expression in patients with bacillus calmette-gu\u00e9rin-exposed non-muscle-invasive bladder cancer. European Urology Oncology, 7(4), 760\u2013769. https:\/\/doi.org\/10.1016\/j.euo.2023.10.003","DOI":"10.1016\/j.euo.2023.10.003"},{"key":"10353_CR160","doi-asserted-by":"publisher","unstructured":"Wang, S., Ji, Y., Liu, Y., Du, P., Ma, J., Yang, X., \u2026 & Yang, Y. (2023). The values of HER-2 expression in the non-muscle-invasive bladder cancer: A retrospective clinical study. Frontiers in Oncology, 13, 1243118. https:\/\/doi.org\/10.3389\/fonc.2023.1243118","DOI":"10.3389\/fonc.2023.1243118"},{"issue":"4","key":"10353_CR161","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/2090598X.2020.1814183","volume":"18","author":"V Agrawal","year":"2020","unstructured":"Agrawal, V., Bharti, N., & Pandey, R. (2020). Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy. Arab Journal of Urology, 18(4), 267\u2013272. https:\/\/doi.org\/10.1080\/2090598X.2020.1814183","journal-title":"Arab Journal of Urology"},{"issue":"1","key":"10353_CR162","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.anndiagpath.2013.10.006","volume":"18","author":"S Jung","year":"2014","unstructured":"Jung, S., Wu, C., Eslami, Z., Tanguay, S., Aprikian, A., Kassouf, W., & Brimo, F. (2014). The role of immunohistochemistry in the diagnosis of flat urothelial lesions: A study using CK20, CK5\/6, P53, Cd138, and Her2\/neu. Annals of Diagnostic Pathology, 18(1), 27\u201332. https:\/\/doi.org\/10.1016\/j.anndiagpath.2013.10.006","journal-title":"Annals of Diagnostic Pathology"},{"issue":"10","key":"10353_CR163","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3390\/medicina61101759","volume":"61","author":"E Kraevska","year":"2025","unstructured":"Kraevska, E., & Popovska, S. (2025). Analysis of HER2 expression in different histological subtypes and IHC-based molecular variants of muscle-invasive bladder carcinoma. Medicina, 61(10), 1759. https:\/\/doi.org\/10.3390\/medicina61101759","journal-title":"Medicina"},{"key":"10353_CR164","doi-asserted-by":"publisher","unstructured":"Dernbach, G., Eich, M.-L., Dragomir, M. P., Anders, P., Jurczok, N., Stief, C., \u2026 & Schallenberg, S. (2025). Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: Implications for pathological and clinical management. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 38(7), 100753. https:\/\/doi.org\/10.1016\/j.modpat.2025.100753","DOI":"10.1016\/j.modpat.2025.100753"},{"key":"10353_CR165","doi-asserted-by":"publisher","unstructured":"Comp\u00e9rat, E., Roupret, M., Yaxley, J., Reynolds, J., Varinot, J., Ouza\u00efd, I., \u2026 & Samaratunga, H. (2010). Micropapillary urothelial carcinoma of the urinary bladder: A clinicopathological analysis of 72 cases. Pathology, 42(7), 650\u2013654. https:\/\/doi.org\/10.3109\/00313025.2010.522173","DOI":"10.3109\/00313025.2010.522173"},{"key":"10353_CR166","doi-asserted-by":"publisher","unstructured":"Zinnall, U., Weyerer, V., Comp\u00e9rat, E., Camparo, P., Gaisa, N. T., Knuechel-Clarke, R., \u2026 & Bertz, S. (2018). Micropapillary urothelial carcinoma: Evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Human Pathology, 80, 55\u201364. https:\/\/doi.org\/10.1016\/j.humpath.2018.05.022","DOI":"10.1016\/j.humpath.2018.05.022"},{"key":"10353_CR167","doi-asserted-by":"publisher","unstructured":"Isharwal, S., Huang, H., Nanjangud, G., Audenet, F., Chen, Y.-B., Gopalan, A., \u2026 & Al-Ahmadie, H. A. (2018). Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Human Pathology, 77, 63\u201369. https:\/\/doi.org\/10.1016\/j.humpath.2018.03.015","DOI":"10.1016\/j.humpath.2018.03.015"},{"key":"10353_CR168","doi-asserted-by":"publisher","unstructured":"Shen, Y., Zheng, L., Zhao, J., Wang, Y., Chen, H., Roy-Chowdhuri, S., \u2026 & Guo, C. C. (2025). Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing. Human Pathology, 159, 105812. https:\/\/doi.org\/10.1016\/j.humpath.2025.105812","DOI":"10.1016\/j.humpath.2025.105812"},{"key":"10353_CR169","doi-asserted-by":"publisher","unstructured":"Kamoun, A., de Reyni\u00e8s, A., Allory, Y., Sj\u00f6dahl, G., Robertson, A. G., Seiler, R., \u2026 & Bladder Cancer Molecular Taxonomy Group. (2020). A consensus molecular classification of muscle-invasive bladder cancer. European Urology, 77(4), 420\u2013433. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006","DOI":"10.1016\/j.eururo.2019.09.006"},{"key":"10353_CR170","doi-asserted-by":"publisher","unstructured":"Guo, C. C., Lee, S., Lee, J. G., Chen, H., Zaleski, M., Choi, W., \u2026 & Czerniak, B. (2024). Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nature Reviews Urology, 21(7), 391\u2013405. https:\/\/doi.org\/10.1038\/s41585-023-00847-7","DOI":"10.1038\/s41585-023-00847-7"},{"key":"10353_CR171","doi-asserted-by":"publisher","unstructured":"Li, J., Shan, K., Huang, W., Su, Q., Qi, Y., Zhang, Z., \u2026 & Du, E. (2024). The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer. Frontiers in Immunology, 15, 1432586. https:\/\/doi.org\/10.3389\/fimmu.2024.1432586","DOI":"10.3389\/fimmu.2024.1432586"},{"key":"10353_CR172","doi-asserted-by":"publisher","unstructured":"Grigg, C. M., Livasy, C., He, J., Hartman, A., Clark, P. E., Zhu, J., \u2026 & Burgess, E. F. (2021). Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity. Human Pathology, 107, 96\u2013103. https:\/\/doi.org\/10.1016\/j.humpath.2020.10.006","DOI":"10.1016\/j.humpath.2020.10.006"},{"issue":"9","key":"10353_CR173","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1016\/j.asjsur.2024.04.161","volume":"47","author":"J Ye","year":"2024","unstructured":"Ye, J., Zhang, M., & Bao, Y. (2024). Discordance of HER2 expression in primary and recurrent\/metastatic urothelial carcinoma in the upper tract. Asian Journal of Surgery, 47(9), 3928\u20133929. https:\/\/doi.org\/10.1016\/j.asjsur.2024.04.161","journal-title":"Asian Journal of Surgery"},{"key":"10353_CR174","doi-asserted-by":"publisher","unstructured":"Gallucci, M., Merola, R., Leonardo, C., Ruggeri, E. M., & Cianciulli, A. M. (2005). Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU International, 96(3), 440; author reply 440\u2013441. https:\/\/doi.org\/10.1111\/j.1464-410X.2005.05755_1.x","DOI":"10.1111\/j.1464-410X.2005.05755_1.x"},{"key":"10353_CR175","doi-asserted-by":"publisher","unstructured":"Gouda, M. A., Gonugunta, A., Dumbrava, E. E., Yap, T. A., Rodon, J., Piha-Paul, S. A., \u2026 & Meric-Bernstam, F. (2025). Human epidermal growth factor receptor 2 loss following treatment with trastuzumab deruxtecan in patients with metastatic breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 31(7), 1268\u20131274. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3468","DOI":"10.1158\/1078-0432.CCR-24-3468"},{"key":"10353_CR176","doi-asserted-by":"publisher","unstructured":"Soria, F., Moschini, M., Haitel, A., Wirth, G. J., Karam, J. A., Wood, C. G., \u2026 & Shariat, S. F. (2017). HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology, 35(2), 251\u2013259. https:\/\/doi.org\/10.1007\/s00345-016-1871-x","DOI":"10.1007\/s00345-016-1871-x"},{"issue":"6","key":"10353_CR177","first-page":"2439","volume":"30","author":"L Izquierdo","year":"2010","unstructured":"Izquierdo, L., Truan, D., Mengual, L., Mallofr\u00e9, C., & Alcaraz, A. (2010). HER-2\/AKT expression in upper urinary tract urothelial carcinoma: Prognostic implications. Anticancer Research, 30(6), 2439\u20132445.","journal-title":"Anticancer Research"},{"issue":"1","key":"10353_CR178","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s43046-020-00047-z","volume":"32","author":"N Missaoui","year":"2020","unstructured":"Missaoui, N., Bdioui, A., Baccouche, A., Belkacem, O., Hmida, W., Mokni, M., & Hmissa, S. (2020). Significance of p53, p27, ki-67, E-cadherin, and HER2 expression in upper urinary tract urothelial carcinoma. Journal of the Egyptian National Cancer Institute, 32(1), 36. https:\/\/doi.org\/10.1186\/s43046-020-00047-z","journal-title":"Journal of the Egyptian National Cancer Institute"},{"issue":"4","key":"10353_CR179","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000475410","volume":"26","author":"B Bjerkehagen","year":"1994","unstructured":"Bjerkehagen, B., Foss\u00e5, S. D., Raabe, N., Holm, R., & Nesland, J. M. (1994). Transitional cell carcinoma of the renal pelvis and its expression of p53 protein, c-erbB-2 protein, neuron-specific enolase, phe 5, chromogranin, laminin and collagen type IV. European Urology, 26(4), 334\u2013339. https:\/\/doi.org\/10.1159\/000475410","journal-title":"European Urology"},{"key":"10353_CR180","doi-asserted-by":"publisher","unstructured":"Ma, D., Dai, L.-J., Wu, X.-R., Liu, C.-L., Zhao, S., Zhang, H., \u2026 & Shao, Z.-M. (2025). Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. Cancer Cell, 43(6), 1061\u20131075.e7. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.017","DOI":"10.1016\/j.ccell.2025.03.017"},{"issue":"1","key":"10353_CR181","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13000-023-01295-y","volume":"18","author":"DS Helal","year":"2023","unstructured":"Helal, D. S., Darwish, S. A., Awad, R. A., Ali, D. A., & El-Guindy, D. M. (2023). Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: Association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival. Diagnostic Pathology, 18(1), 11. https:\/\/doi.org\/10.1186\/s13000-023-01295-y","journal-title":"Diagnostic Pathology"},{"key":"10353_CR182","doi-asserted-by":"publisher","unstructured":"Bai, X., He, W., Yin, H., Li, X., Zhou, X., Wei, Z., \u2026 & Gou, X. (2022). Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single\u2011center experience. Experimental and Therapeutic Medicine, 24(5), 704. https:\/\/doi.org\/10.3892\/etm.2022.11640","DOI":"10.3892\/etm.2022.11640"},{"issue":"8","key":"10353_CR183","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/j.1464-410X.2009.09190.x","volume":"106","author":"C Bolenz","year":"2010","unstructured":"Bolenz, C., Shariat, S. F., Karakiewicz, P. I., Ashfaq, R., Ho, R., Sagalowsky, A. I., & Lotan, Y. (2010). Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU International, 106(8), 1216\u20131222. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.09190.x","journal-title":"BJU International"},{"issue":"2","key":"10353_CR184","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","volume":"60","author":"A Fleischmann","year":"2011","unstructured":"Fleischmann, A., Rotzer, D., Seiler, R., Studer, U. E., & Thalmann, G. N. (2011). Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. European Urology, 60(2), 350\u2013357. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.035","journal-title":"European Urology"},{"issue":"2","key":"10353_CR185","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jclinpath-2012-200944","volume":"66","author":"PC-H Chen","year":"2013","unstructured":"Chen, P.C.-H., Yu, H.-J., Chang, Y.-H., & Pan, C.-C. (2013). Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. Journal of Clinical Pathology, 66(2), 113\u2013119. https:\/\/doi.org\/10.1136\/jclinpath-2012-200944","journal-title":"Journal of Clinical Pathology"},{"key":"10353_CR186","unstructured":"Sasaki, Y., Sasaki, T., Kawai, T., Morikawa, T., Matsusaka, K., Kunita, A., \u2026 & Fukayama, M. (2014). HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients. International Journal of Clinical and Experimental Pathology, 7(2), 699\u2013708."},{"key":"10353_CR187","doi-asserted-by":"publisher","unstructured":"Ding, W., Tong, S., Gou, Y., Sun, C., Wang, H., Chen, Z., \u2026 & Ding, Q. (2015). Human epidermal growth factor receptor 2: A significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World Journal of Urology, 33(12), 1951\u20131957. https:\/\/doi.org\/10.1007\/s00345-015-1557-9","DOI":"10.1007\/s00345-015-1557-9"},{"key":"10353_CR188","doi-asserted-by":"publisher","unstructured":"Nedjadi, T., Al-Maghrabi, J., Assidi, M., Dallol, A., Al-Kattabi, H., Chaudhary, A., \u2026 & Al-Qahtani, M. (2016). Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer, 16(1), 653. https:\/\/doi.org\/10.1186\/s12885-016-2703-5","DOI":"10.1186\/s12885-016-2703-5"},{"key":"10353_CR189","doi-asserted-by":"publisher","unstructured":"El Ochi, M. R., Oukabli, M., Bouaiti, E., Chahdi, H., Boudhas, A., Allaoui, M., \u2026 & Al Bouzidi, A. (2017). Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. BMC clinical pathology, 17, 3. https:\/\/doi.org\/10.1186\/s12907-017-0046-z","DOI":"10.1186\/s12907-017-0046-z"},{"key":"10353_CR190","doi-asserted-by":"publisher","unstructured":"Cormio, L., Sanguedolce, F., Cormio, A., Massenio, P., Pedicillo, M. C., Cagiano, S., \u2026 & Bufo, P. (2017). Human epidermal growth factor receptor 2 expression is more important than bacillus calmette guerin treatment in predicting the outcome of T1G3 bladder cancer. Oncotarget, 8(15), 25433\u201325441. https:\/\/doi.org\/10.18632\/oncotarget.15989","DOI":"10.18632\/oncotarget.15989"},{"key":"10353_CR191","doi-asserted-by":"publisher","unstructured":"Kriegmair, M. C., Wirtz, R. M., Worst, T. S., Breyer, J., Ritter, M., Keck, B., \u2026 & Erben, P. (2018). Prognostic value of molecular breast cancer subtypes based on Her2, ESR1, PGR and Ki67 mRNA-expression in muscle invasive bladder cancer. Translational Oncology, 11(2), 467\u2013476. https:\/\/doi.org\/10.1016\/j.tranon.2018.02.001","DOI":"10.1016\/j.tranon.2018.02.001"},{"key":"10353_CR192","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.anndiagpath.2019.01.002","volume":"39","author":"AE Abdelrahman","year":"2019","unstructured":"Abdelrahman, A. E., Rashed, H. E., Elkady, E., Elsebai, E. A., El-Azony, A., & Matar, I. (2019). Fatty acid synthase, Her2\/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer. Annals of Diagnostic Pathology, 39, 42\u201352. https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.01.002","journal-title":"Annals of Diagnostic Pathology"},{"issue":"1","key":"10353_CR193","doi-asserted-by":"publisher","first-page":"300060519895847","DOI":"10.1177\/0300060519895847","volume":"48","author":"G Moustakas","year":"2020","unstructured":"Moustakas, G., Kampantais, S., Nikolaidou, A., Vakalopoulos, I., Tzioufa, V., & Dimitriadis, G. (2020). HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy. The Journal of International Medical Research, 48(1), 300060519895847. https:\/\/doi.org\/10.1177\/0300060519895847","journal-title":"The Journal of International Medical Research"},{"key":"10353_CR194","doi-asserted-by":"publisher","unstructured":"Xu, H., Sheng, X., Zhou, L., Yan, X., Li, S., Chi, Z., \u2026 & Guo, J. (2022). A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma. Journal of Clinical Oncology, 40(16_suppl), 4519\u20134519. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4519","DOI":"10.1200\/JCO.2022.40.16_suppl.4519"},{"key":"10353_CR195","doi-asserted-by":"publisher","unstructured":"Rizzo, A., Mollica, V., Giunchi, F., Dall\u2019Olio, F. G., Rosellini, M., Marchetti, A., \u2026 & Massari, F. (2021). Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. Pathology, Research and Practice, 220, 153410. https:\/\/doi.org\/10.1016\/j.prp.2021.153410","DOI":"10.1016\/j.prp.2021.153410"},{"key":"10353_CR196","doi-asserted-by":"publisher","unstructured":"Chae, H. K., Nam, W., Kim, H. G., Lim, S., Noh, B.-J., Kim, S. W., \u2026 & Kim, S. J. (2022). Identification of new prognostic markers and therapeutic targets for non-muscle invasive bladder cancer: HER2 as a potential target antigen. Frontiers in Immunology, 13, 903297. https:\/\/doi.org\/10.3389\/fimmu.2022.903297","DOI":"10.3389\/fimmu.2022.903297"},{"issue":"2","key":"10353_CR197","first-page":"245","volume":"44","author":"N Rosli","year":"2022","unstructured":"Rosli, N., Mahasin, M., Mohd Saleh, M. F., & Abd Shukor, N. (2022). The prognostic significance of HER2 expression in urothelial carcinoma. The Malaysian Journal of Pathology, 44(2), 245\u2013252.","journal-title":"The Malaysian Journal of Pathology"},{"key":"10353_CR198","doi-asserted-by":"publisher","unstructured":"Rodriguez Pena, M. D. C., Chaux, A., Eich, M.-L., Tregnago, A. C., Taheri, D., Borhan, W., \u2026 & Netto, G. J. (2019). Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. Virchows Archiv, 475(3), 349\u2013356. https:\/\/doi.org\/10.1007\/s00428-019-02618-5","DOI":"10.1007\/s00428-019-02618-5"},{"key":"10353_CR199","doi-asserted-by":"publisher","unstructured":"Li, S., Wu, X., Yan, X., Zhou, L., Xu, H., Li, J., \u2026 & Sheng, X. (2022). Prognostic value of HER2 expression levels for upper tract urothelial carcinoma. Journal of Clinical Oncology, 40(6_suppl), 557\u2013557. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.557","DOI":"10.1200\/JCO.2022.40.6_suppl.557"},{"key":"10353_CR200","doi-asserted-by":"publisher","unstructured":"Zhang, L., Jin, D., Zang, J., Qian, L., Zhang, T., Wu, Y., \u2026 & Chen, H. (2025). Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: A proof-of-concept study. Neoplasia, 68, 101216. https:\/\/doi.org\/10.1016\/j.neo.2025.101216","DOI":"10.1016\/j.neo.2025.101216"},{"issue":"5","key":"10353_CR201","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.urolonc.2009.08.002","volume":"29","author":"HM Behnsawy","year":"2011","unstructured":"Behnsawy, H. M., Miyake, H., Abdalla, M. A., Sayed, M. A., Ahmed, A.E.-F.I., & Fujisawa, M. (2011). Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: Correlation with intravesical recurrence following transurethral resection. Urologic Oncology, 29(5), 495\u2013501. https:\/\/doi.org\/10.1016\/j.urolonc.2009.08.002","journal-title":"Urologic Oncology"},{"key":"10353_CR202","doi-asserted-by":"publisher","unstructured":"Soria, F., Moschini, M., Haitel, A., Wirth, G. J., Gust, K. M., Briganti, A., \u2026 & Shariat, S. F. (2016). The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. Urologic Oncology, 34(12), 533.e1\u2013533.e10. https:\/\/doi.org\/10.1016\/j.urolonc.2016.07.006","DOI":"10.1016\/j.urolonc.2016.07.006"},{"key":"10353_CR203","doi-asserted-by":"publisher","unstructured":"Ge, H., Liu, C., Shen, C., Hu, D., Zhao, X., Wang, Y., \u2026 & Wang, Y. (2025). The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: A multicenter, real-world study. Journal of Translational Medicine, 23(1), 243. https:\/\/doi.org\/10.1186\/s12967-025-06237-4","DOI":"10.1186\/s12967-025-06237-4"},{"key":"10353_CR204","doi-asserted-by":"publisher","unstructured":"Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., \u2026 & DESTINY-Breast04 Trial Investigators. (2022). Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. The New England Journal of Medicine, 387(1), 9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","DOI":"10.1056\/NEJMoa2203690"},{"key":"10353_CR205","doi-asserted-by":"publisher","unstructured":"Bardia, A., Hu, X., Dent, R., Yonemori, K., Barrios, C. H., O\u2019Shaughnessy, J. A., \u2026 & DESTINY-Breast06 Trial Investigators. (2024). Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. The New England Journal of Medicine, 391(22), 2110\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa2407086","DOI":"10.1056\/NEJMoa2407086"},{"key":"10353_CR206","doi-asserted-by":"publisher","unstructured":"Yan, X., Li, J., Xu, H., Liu, Y., Zhou, L., Li, S., \u2026 & Sheng, X. (2025). Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study. Med, 6(7), 100637. https:\/\/doi.org\/10.1016\/j.medj.2025.100637","DOI":"10.1016\/j.medj.2025.100637"},{"key":"10353_CR207","doi-asserted-by":"publisher","unstructured":"Franchina, M., Pizzimenti, C., Fiorentino, V., Martini, M., Ricciardi, G. R. R., Silvestris, N., \u2026 & Tuccari, G. (2023). Low and ultra-low HER2 in human breast cancer: An effort to define new neoplastic subtypes. International Journal of Molecular Sciences, 24(16), 12795. https:\/\/doi.org\/10.3390\/ijms241612795","DOI":"10.3390\/ijms241612795"},{"issue":"6","key":"10353_CR208","doi-asserted-by":"publisher","first-page":"oyaf081","DOI":"10.1093\/oncolo\/oyaf081","volume":"30","author":"G Munk\u00e1csy","year":"2025","unstructured":"Munk\u00e1csy, G., Santarpia, L., & Gy\u0151rffy, B. (2025). Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes. The Oncologist, 30(6), oyaf081. https:\/\/doi.org\/10.1093\/oncolo\/oyaf081","journal-title":"The Oncologist"},{"key":"10353_CR209","doi-asserted-by":"publisher","unstructured":"McKelvey, B., Torres-Saavedra, P. A., Li, J., Broeckx, G., Deman, F., Ali, S., \u2026 & Allen, J. (2026). Agreement across 10 artificial intelligence models in assessing human epidermal growth factor receptor 2 (HER2) expression in breast cancer whole-slide images. Modern Pathology, 39(2), 100944. https:\/\/doi.org\/10.1016\/j.modpat.2025.100944","DOI":"10.1016\/j.modpat.2025.100944"},{"key":"10353_CR210","doi-asserted-by":"publisher","unstructured":"Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., \u2026 & Curigliano, G. (2023). ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(8), 645\u2013659. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.008","DOI":"10.1016\/j.annonc.2023.05.008"},{"key":"10353_CR211","doi-asserted-by":"publisher","unstructured":"Sompuram, S. R., Vani, K., Ryan, L., Johnson, C., Szabolcs, M., Peruyero, L., \u2026 & Bogen, S. A. (2023). Validation of linear range HER2\/estrogen receptor\/progesterone receptor IHControls for daily quality assurance. American Journal of Clinical Pathology, 159(3), 274\u2013282. https:\/\/doi.org\/10.1093\/ajcp\/aqac163","DOI":"10.1093\/ajcp\/aqac163"},{"issue":"9","key":"10353_CR212","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1369\/0022155415588109","volume":"63","author":"SR Sompuram","year":"2015","unstructured":"Sompuram, S. R., Vani, K., Tracey, B., Kamstock, D. A., & Bogen, S. A. (2015). Standardizing immunohistochemistry: A new reference control for detecting staining problems. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society, 63(9), 681\u2013690. https:\/\/doi.org\/10.1369\/0022155415588109","journal-title":"The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society"},{"key":"10353_CR213","doi-asserted-by":"publisher","unstructured":"Yousif, M., Huang, Y., Sciallis, A., Kleer, C. G., Pang, J., Smola, B., \u2026 & Pantanowitz, L. (2022). Quantitative image analysis as an adjunct to manual scoring of ER, PgR, and HER2 in invasive breast carcinoma. American Journal of Clinical Pathology, 157(6), 899\u2013907. https:\/\/doi.org\/10.1093\/ajcp\/aqab206","DOI":"10.1093\/ajcp\/aqab206"},{"key":"10353_CR214","doi-asserted-by":"publisher","unstructured":"Kapil, A., Spitzm\u00fcller, A., Brieu, N., Haneder, S., Shumilov, A., Meier, A., \u2026 & Carroll, D. (2024). HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer. Scientific Reports, 14(1), 12129. https:\/\/doi.org\/10.1038\/s41598-024-61957-9","DOI":"10.1038\/s41598-024-61957-9"},{"key":"10353_CR215","doi-asserted-by":"publisher","unstructured":"Xu, B., Chen, H., Zhang, J., Cong, Y., Ning, L., Chen, L., \u2026 & Zhao, F. (2023). A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification. Frontiers in Oncology, 13, 1152895. https:\/\/doi.org\/10.3389\/fonc.2023.1152895","DOI":"10.3389\/fonc.2023.1152895"},{"key":"10353_CR216","doi-asserted-by":"publisher","unstructured":"Moutafi, M., Robbins, C. J., Yaghoobi, V., Fernandez, A. I., Martinez-Morilla, S., Xirou, V., \u2026 & Rimm, D. L. (2022). Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Laboratory Investigation; a Journal of Technical Methods and Pathology, 102(10), 1101\u20131108. https:\/\/doi.org\/10.1038\/s41374-022-00804-9","DOI":"10.1038\/s41374-022-00804-9"},{"key":"10353_CR217","doi-asserted-by":"publisher","unstructured":"Liu, M., Vathiotis, I., Robbins, C. J., Chan, N. N. N., Moutafi, M., Burela, S., \u2026 & Rimm, D. L. (2024). Quantitative measurement of HER2 expression in non-small cell lung cancer with a high-sensitivity assay. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 37(9), 100556. https:\/\/doi.org\/10.1016\/j.modpat.2024.100556","DOI":"10.1016\/j.modpat.2024.100556"},{"key":"10353_CR218","doi-asserted-by":"publisher","unstructured":"Gupta, S., Neumeister, V., McGuire, J., Song, Y. S., Acs, B., Ho, K., \u2026 & Bossuyt, V. (2019). Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO\/CAP ISH group 4 breast cancer. NPJ Breast Cancer, 5, 28. https:\/\/doi.org\/10.1038\/s41523-019-0122-x","DOI":"10.1038\/s41523-019-0122-x"},{"key":"10353_CR219","doi-asserted-by":"publisher","unstructured":"Kacerovsky-Strobl, S., Deutschmann, C., Hlauschek, D., Bago-Horvath, Z., Singer, C. F., Bartsch, R., \u2026 & Filipits, M. (2025). ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG trial 34. Breast, 84, 104633. https:\/\/doi.org\/10.1016\/j.breast.2025.104633","DOI":"10.1016\/j.breast.2025.104633"},{"key":"10353_CR220","doi-asserted-by":"publisher","unstructured":"Hu, J., Yan, L., Liu, J., Chen, M., Liu, P., Deng, D., \u2026 & Zu, X. (2025). Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study. iMeta, 4(3), e70033. https:\/\/doi.org\/10.1002\/imt2.70033","DOI":"10.1002\/imt2.70033"},{"key":"10353_CR221","doi-asserted-by":"publisher","unstructured":"Lindskrog, S. V., Strandgaard, T., Nordentoft, I., Galsky, M. D., Powles, T., Agerb\u00e6k, M., \u2026 & Dyrskj\u00f8t, L. (2025). Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation. Nature Reviews. Urology, 22(9), 590\u2013608. https:\/\/doi.org\/10.1038\/s41585-025-01023-9","DOI":"10.1038\/s41585-025-01023-9"},{"issue":"2","key":"10353_CR222","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/CU9.0000000000000091","volume":"16","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi, M., Abe, H., Arai, K., Murakami, S., & Kamai, T. (2022). Circulating tumor cells and cell-free tumor DNA analyses in urothelial cancer using the LiquidBiopsy platform. Current Urology, 16(2), 99\u2013106. https:\/\/doi.org\/10.1097\/CU9.0000000000000091","journal-title":"Current Urology"},{"key":"10353_CR223","doi-asserted-by":"publisher","unstructured":"Vandekerkhove, G., Todenh\u00f6fer, T., Annala, M., Struss, W. J., Wong, A., Beja, K., \u2026 & Wyatt, A. W. (2017). Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23(21), 6487\u20136497. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1140","DOI":"10.1158\/1078-0432.CCR-17-1140"},{"key":"10353_CR224","doi-asserted-by":"publisher","unstructured":"Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., \u2026 & Diaz, L. A. (2014). Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine, 6(224), 224ra24. https:\/\/doi.org\/10.1126\/scitranslmed.3007094","DOI":"10.1126\/scitranslmed.3007094"},{"key":"10353_CR225","doi-asserted-by":"publisher","unstructured":"Yoshida, K., Tsuda, M., Matsumoto, R., Semba, S., Wang, L., Sugino, H., \u2026 & Tanaka, S. (2019). Exosomes containing ErbB2\/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer. Cancer Science, 110(7), 2119\u20132132. https:\/\/doi.org\/10.1111\/cas.14080","DOI":"10.1111\/cas.14080"},{"issue":"7","key":"10353_CR226","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3390\/nano11071853","volume":"11","author":"V Vinduska","year":"2021","unstructured":"Vinduska, V., Gallops, C. E., O\u2019Connor, R., Wang, Y., & Huang, X. (2021). Exosomal surface protein detection with quantum dots and immunomagnetic capture for cancer detection. Nanomaterials, 11(7), 1853. https:\/\/doi.org\/10.3390\/nano11071853","journal-title":"Nanomaterials"},{"key":"10353_CR227","doi-asserted-by":"publisher","unstructured":"Jia, Y., Li, Y., Bai, X., Liu, L., Shan, Y., Wang, F., \u2026 & Zheng, C. (2025). Raman spectroscopy and exosome-based machine learning predicts the efficacy of neoadjuvant therapy for HER2-positive breast cancer. Analytical Chemistry, 97(2), 1374\u20131385. https:\/\/doi.org\/10.1021\/acs.analchem.4c05833","DOI":"10.1021\/acs.analchem.4c05833"},{"issue":"Supplement","key":"10353_CR228","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.4103\/0971-5916.191769","volume":"143","author":"S Shukla","year":"2016","unstructured":"Shukla, S., Singh, B. K., Pathania, O. P., & Jain, M. (2016). Evaluation of HER2\/neu oncoprotein in serum & tissue samples of women with breast cancer. The Indian Journal of Medical Research, 143(Supplement), S52\u2013S58. https:\/\/doi.org\/10.4103\/0971-5916.191769","journal-title":"The Indian Journal of Medical Research"},{"key":"10353_CR229","doi-asserted-by":"publisher","unstructured":"Kong, Y., Dai, S., Xie, X., Xiao, X., Lv, N., Guo, J., \u2026 & Xie, X. (2012). High serum HER2 extracellular domain levels: Correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. Journal of Cancer Research and Clinical Oncology, 138(2), 275\u2013284. https:\/\/doi.org\/10.1007\/s00432-011-1095-9","DOI":"10.1007\/s00432-011-1095-9"},{"key":"10353_CR230","doi-asserted-by":"publisher","unstructured":"Oyama, K., Fushida, S., Tsukada, T., Kinoshita, J., Watanabe, T., Shoji, M., \u2026 & Ohta, T. (2015). Evaluation of serum HER2-ECD levels in patients with gastric cancer. Journal of Gastroenterology, 50(1), 41\u201345. https:\/\/doi.org\/10.1007\/s00535-014-0941-3","DOI":"10.1007\/s00535-014-0941-3"},{"issue":"10","key":"10353_CR231","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00604-021-04963-2","volume":"188","author":"R Ahirwar","year":"2021","unstructured":"Ahirwar, R. (2021). Recent advances in nanomaterials-based electrochemical immunosensors and aptasensors for HER2 assessment in breast cancer. Mikrochimica Acta, 188(10), 317. https:\/\/doi.org\/10.1007\/s00604-021-04963-2","journal-title":"Mikrochimica Acta"},{"key":"10353_CR232","doi-asserted-by":"publisher","unstructured":"Luo, C., Li, S., Han, Y., Ling, J., Wu, X., Chen, L., \u2026 & Chen, J. (2025). Noninvasive identification of HER2 status by integrating multiparametric MRI-based radiomics model with the vesical imaging-reporting and data system (VI-RADS) score in bladder urothelial carcinoma. Abdominal Radiology, 50(7), 3126\u20133136. https:\/\/doi.org\/10.1007\/s00261-024-04767-x","DOI":"10.1007\/s00261-024-04767-x"},{"key":"10353_CR233","doi-asserted-by":"publisher","unstructured":"Zhuang, J., Chen, Y., Zheng, W., Lian, G., Zhu, Y., Zhang, H., \u2026 & Ye, Q. (2026). Prediction of HER2 expression in urothelial carcinoma of the bladder: Are ultrasound-based radiomic features significant? Ultrasound in Medicine & Biology, 52(1), 190\u2013200. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2025.09.013","DOI":"10.1016\/j.ultrasmedbio.2025.09.013"},{"issue":"8","key":"10353_CR234","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ccell.2025.07.008","volume":"43","author":"CS Dai","year":"2025","unstructured":"Dai, C. S., Mishra, A., Edd, J., Toner, M., Maheswaran, S., & Haber, D. A. (2025). Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications. Cancer Cell, 43(8), 1399\u20131422. https:\/\/doi.org\/10.1016\/j.ccell.2025.07.008","journal-title":"Cancer Cell"},{"issue":"11","key":"10353_CR235","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.trecan.2021.07.001","volume":"7","author":"E Schuster","year":"2021","unstructured":"Schuster, E., Taftaf, R., Reduzzi, C., Albert, M. K., Romero-Calvo, I., & Liu, H. (2021). Better together: Circulating tumor cell clustering in metastatic cancer. Trends in Cancer, 7(11), 1020\u20131032. https:\/\/doi.org\/10.1016\/j.trecan.2021.07.001","journal-title":"Trends in Cancer"},{"issue":"1","key":"10353_CR236","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev-pathol-052016-100256","volume":"12","author":"J-A Thiele","year":"2017","unstructured":"Thiele, J.-A., Bethel, K., Kr\u00e1l\u00ed\u010dkov\u00e1, M., & Kuhn, P. (2017). Circulating tumor cells: Fluid surrogates of solid tumors. Annual Review of Pathology: Mechanisms of Disease, 12(1), 419\u2013447. https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100256","journal-title":"Annual Review of Pathology: Mechanisms of Disease"},{"key":"10353_CR237","doi-asserted-by":"publisher","unstructured":"Rink, M., Chun, F. K., Dahlem, R., Soave, A., Minner, S., Hansen, J., \u2026 & Riethdorf, S. (2012). Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: A prospective study. European Urology, 61(4), 810\u2013817. https:\/\/doi.org\/10.1016\/j.eururo.2012.01.017","DOI":"10.1016\/j.eururo.2012.01.017"},{"key":"10353_CR238","doi-asserted-by":"publisher","unstructured":"Chen, W., Zhang, J., Huang, L., Chen, L., Zhou, Y., Tang, D., \u2026 & Huang, C. (2019). Detection of HER2-positive circulating tumor cells using the LiquidBiopsy system in breast cancer. Clinical Breast Cancer, 19(1), e239\u2013e246. https:\/\/doi.org\/10.1016\/j.clbc.2018.10.009","DOI":"10.1016\/j.clbc.2018.10.009"},{"key":"10353_CR239","doi-asserted-by":"publisher","unstructured":"Mayer, J. A., Pham, T., Wong, K. L., Scoggin, J., Sales, E. V., Clarin, T., \u2026 & Bischoff, F. Z. (2011). FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEETM platform. Cancer Genetics, 204(11), 589\u2013595. https:\/\/doi.org\/10.1016\/j.cancergen.2011.10.011","DOI":"10.1016\/j.cancergen.2011.10.011"},{"key":"10353_CR240","doi-asserted-by":"publisher","unstructured":"Nini, A., Hoffmann, M. J., Lampignano, R., Gro\u00dfe Siemer, R., van Dalum, G., Szarvas, T., \u2026 & Niegisch, G. (2020). Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. Cytometry. Part B, Clinical Cytometry, 98(4), 355\u2013367. https:\/\/doi.org\/10.1002\/cyto.b.21877","DOI":"10.1002\/cyto.b.21877"},{"key":"10353_CR241","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-1-0716-2193-6_18","volume-title":"Mammary stem cells","author":"R Burr","year":"2022","unstructured":"Burr, R., Edd, J. F., Chirn, B., Mishra, A., Haber, D. A., Toner, M., & Maheswaran, S. (2022). Negative-selection enrichment of circulating tumor cells from peripheral blood using the microfluidic CTC-iChip. In Md. M. Vivanco (Ed.), Mammary stem cells (Vol. Vol. 2471, pp. 309\u2013321). Springer US. https:\/\/doi.org\/10.1007\/978-1-0716-2193-6_18"},{"key":"10353_CR242","doi-asserted-by":"publisher","unstructured":"Wu, M., Huang, P., Zhang, R., Mao, Z., Chen, C., Kemeny, G., \u2026 & Huang, T. J. (2018). Circulating tumor cell phenotyping via high\u2010throughput acoustic separation. Small, 14(32), 1801131. https:\/\/doi.org\/10.1002\/smll.201801131","DOI":"10.1002\/smll.201801131"},{"key":"10353_CR243","doi-asserted-by":"publisher","unstructured":"M\u00fcller, V., Banys-Paluchowski, M., Friedl, T. W. P., Fasching, P. A., Schneeweiss, A., Hartkopf, A., \u2026 & DETECT study group. (2021). Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO open, 6(6), 100299. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100299","DOI":"10.1016\/j.esmoop.2021.100299"},{"key":"10353_CR244","doi-asserted-by":"publisher","unstructured":"Kimura, Y., Suzuki, K., Tamaki, S., Abe, I., Endo, Y., Ichida, K., \u2026 & Rikiyama, T. (2025). Real-time assessment of circulating tumor cells refines the indication for HER2-targeted therapy in metastatic gastric cancer. Scientific Reports, 15(1), 23906. https:\/\/doi.org\/10.1038\/s41598-025-06913-x","DOI":"10.1038\/s41598-025-06913-x"},{"key":"10353_CR245","doi-asserted-by":"publisher","unstructured":"Fehm, T., Mueller, V., Banys-Paluchowski, M., Fasching, P. A., Friedl, T. W. P., Hartkopf, A., \u2026 & DETECT Study Group. (2024). Efficacy of lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells-the DETECT III clinical trial. Clinical Chemistry, 70(1), 307\u2013318. https:\/\/doi.org\/10.1093\/clinchem\/hvad144","DOI":"10.1093\/clinchem\/hvad144"},{"key":"10353_CR246","doi-asserted-by":"publisher","unstructured":"Niu, Z., Kozminsky, M., Day, K. C., Broses, L. J., Henderson, M. L., Patsalis, C., \u2026 & Day, M. L. (2024). Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics. Neoplasia, 57, 101036. https:\/\/doi.org\/10.1016\/j.neo.2024.101036","DOI":"10.1016\/j.neo.2024.101036"},{"key":"10353_CR247","doi-asserted-by":"publisher","unstructured":"De Gregorio, A., Friedl, T. W. P., Huober, J., Scholz, C., De Gregorio, N., Rack, B., \u2026 & Fehm, T. (2017). Discordance in human epidermal growth factor receptor 2 (HER2) phenotype between primary tumor and circulating tumor cells in women with HER2-negative metastatic breast cancer. JCO Precision Oncology, 1, 1\u201312. https:\/\/doi.org\/10.1200\/PO.17.00023","DOI":"10.1200\/PO.17.00023"},{"key":"10353_CR248","doi-asserted-by":"publisher","unstructured":"Xie, P., Zhang, X., Liu, T., Song, Y., Zhang, Q., Wan, D., \u2026 & Zhang, W. (2024). Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer. Discover Oncology, 15(1), 760. https:\/\/doi.org\/10.1007\/s12672-024-01663-0","DOI":"10.1007\/s12672-024-01663-0"},{"key":"10353_CR249","doi-asserted-by":"publisher","unstructured":"Jordan, N. V., Bardia, A., Wittner, B. S., Benes, C., Ligorio, M., Zheng, Y., \u2026 & Haber, D. A. (2016). HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature, 537(7618), 102\u2013106. https:\/\/doi.org\/10.1038\/nature19328","DOI":"10.1038\/nature19328"},{"issue":"9","key":"10353_CR250","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","volume":"19","author":"A Tivey","year":"2022","unstructured":"Tivey, A., Church, M., Rothwell, D., Dive, C., & Cook, N. (2022). Circulating tumour DNA - looking beyond the blood. Nature Reviews. Clinical Oncology, 19(9), 600\u2013612. https:\/\/doi.org\/10.1038\/s41571-022-00660-y","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10353_CR251","doi-asserted-by":"publisher","unstructured":"Wei, Q., Zhang, Y., Gao, J., Li, J., Li, J., Li, Y., \u2026 & Wang, X. (2019). Clinicopathologic characteristics of HER2-positive metastatic colorectal cancer and detection of HER2 in plasma circulating tumor DNA. Clinical Colorectal Cancer, 18(3), 175\u2013182. https:\/\/doi.org\/10.1016\/j.clcc.2019.05.001","DOI":"10.1016\/j.clcc.2019.05.001"},{"key":"10353_CR252","doi-asserted-by":"publisher","unstructured":"Guan, X., Liu, B., Niu, Y., Dong, X., Zhu, X., Li, C., \u2026 & Ma, F. (2020). Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer. Breast, 49, 261\u2013266. https:\/\/doi.org\/10.1016\/j.breast.2019.12.010","DOI":"10.1016\/j.breast.2019.12.010"},{"key":"10353_CR253","doi-asserted-by":"publisher","unstructured":"Vandekerkhove, G., Lavoie, J.-M., Annala, M., Murtha, A. J., Sundahl, N., Walz, S., \u2026 & Wyatt, A. W. (2021). Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications, 12(1), 184. https:\/\/doi.org\/10.1038\/s41467-020-20493-6","DOI":"10.1038\/s41467-020-20493-6"},{"key":"10353_CR254","doi-asserted-by":"publisher","unstructured":"Barata, P. C., Koshkin, V. S., Funchain, P., Sohal, D., Pritchard, A., Klek, S., \u2026 & Grivas, P. (2017). Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: A pilot assessment of concordance. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28(10), 2458\u20132463. https:\/\/doi.org\/10.1093\/annonc\/mdx405","DOI":"10.1093\/annonc\/mdx405"},{"key":"10353_CR255","doi-asserted-by":"publisher","unstructured":"Vandekerkhove, G., Murtha, A. J., M\u00fcller, D. C., Stephenson, M., Rostin, K., Munzur, A. D., \u2026 & Wyatt, A. W. (2025). ERBB2\/HER2 alterations in ctDNA and metachronous tissues of patients with metastatic urothelial cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 31(17), 3725\u20133741. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3912","DOI":"10.1158\/1078-0432.CCR-24-3912"},{"key":"10353_CR256","doi-asserted-by":"publisher","unstructured":"Birkenkamp-Demtr\u00f6der, K., Christensen, E., Nordentoft, I., Knudsen, M., Taber, A., H\u00f8yer, S., \u2026 & Dyrskj\u00f8t, L. (2018). Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. European Urology, 73(4), 535\u2013540. https:\/\/doi.org\/10.1016\/j.eururo.2017.09.011","DOI":"10.1016\/j.eururo.2017.09.011"},{"key":"10353_CR257","doi-asserted-by":"publisher","unstructured":"Christensen, E., Birkenkamp-Demtr\u00f6der, K., Sethi, H., Shchegrova, S., Salari, R., Nordentoft, I., \u2026 & Dyrskj\u00f8t, L. (2019). Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37(18), 1547\u20131557. https:\/\/doi.org\/10.1200\/JCO.18.02052","DOI":"10.1200\/JCO.18.02052"},{"key":"10353_CR258","doi-asserted-by":"publisher","unstructured":"Wang, H., Li, B., Liu, Z., Gong, J., Shao, L., Ren, J., \u2026 & Shen, L. (2018). HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. European Journal of Cancer, 88, 92\u2013100. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.032","DOI":"10.1016\/j.ejca.2017.10.032"},{"key":"10353_CR259","doi-asserted-by":"publisher","unstructured":"Ma, F., Zhu, W., Guan, Y., Yang, L., Xia, X., Chen, S., \u2026 & Xu, B. (2016). ctDNA dynamics: A novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget, 7(40), 66020\u201366031. https:\/\/doi.org\/10.18632\/oncotarget.11791","DOI":"10.18632\/oncotarget.11791"},{"key":"10353_CR260","doi-asserted-by":"publisher","unstructured":"Yu, D., Li, Y., Wang, M., Gu, J., Xu, W., Cai, H., \u2026 & Zhang, X. (2022). Exosomes as a new frontier of cancer liquid biopsy. Molecular Cancer, 21(1), 56. https:\/\/doi.org\/10.1186\/s12943-022-01509-9","DOI":"10.1186\/s12943-022-01509-9"},{"key":"10353_CR261","doi-asserted-by":"publisher","unstructured":"Xu, F., Wang, K., Xu, C., Xu, J., Zhu, C., Zhu, Y., \u2026 & Guan, X. (2025). Enrichment and detection of HER2-expressing extracellular vesicles based on DNA tetrahedral nanostructures: A new strategy for liquid biopsy in breast cancer. Analytical Chemistry, 97(17), 9212\u20139219. https:\/\/doi.org\/10.1021\/acs.analchem.4c06417","DOI":"10.1021\/acs.analchem.4c06417"},{"key":"10353_CR262","doi-asserted-by":"publisher","unstructured":"Fang, S., Tian, H., Li, X., Jin, D., Li, X., Kong, J., \u2026 & Liu, T. (2017). Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification. PloS One, 12(4), e0175050. https:\/\/doi.org\/10.1371\/journal.pone.0175050","DOI":"10.1371\/journal.pone.0175050"},{"key":"10353_CR263","doi-asserted-by":"publisher","unstructured":"Inubushi, S., Kunihisa, T., Kuniyasu, M., Inoue, S., Yamamoto, M., Yamashita, Y., \u2026 & Tanino, H. (2024). Serum exosomes expressing CD9, CD63 and HER2 from breast-cancer patients decreased after surgery of the primary tumor: A potential biomarker of tumor burden. Cancer Genomics & Proteomics, 21(6), 580\u2013584. https:\/\/doi.org\/10.21873\/cgp.20474","DOI":"10.21873\/cgp.20474"},{"issue":"1","key":"10353_CR264","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13058-020-01323-5","volume":"22","author":"A Nanou","year":"2020","unstructured":"Nanou, A., Zeune, L. L., Bidard, F.-C., Pierga, J.-Y., & Terstappen, L. W. M. M. (2020). HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer. Breast cancer research: BCR, 22(1), 86. https:\/\/doi.org\/10.1186\/s13058-020-01323-5","journal-title":"Breast cancer research: BCR"},{"key":"10353_CR265","doi-asserted-by":"publisher","unstructured":"Qui, S., Takeshita, T., Sueta, A., Tomiguchi, M., Goto-Yamaguchi, L., Hidaka, K., \u2026 & Iwase, H. (2021). Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: A comparison with HER2 extracellular domain protein level in serum. Breast Cancer, 28(3), 746\u2013754. https:\/\/doi.org\/10.1007\/s12282-020-01212-x","DOI":"10.1007\/s12282-020-01212-x"},{"key":"10353_CR266","doi-asserted-by":"publisher","unstructured":"Shamshirian, A., Aref, A. R., Yip, G. W., Ebrahimi Warkiani, M., Heydari, K., Razavi Bazaz, S., \u2026 & Alizadeh-Navaei, R. (2020). Diagnostic value of serum HER2 levels in breast cancer: A systematic review and meta-analysis. BMC cancer, 20(1), 1049. https:\/\/doi.org\/10.1186\/s12885-020-07545-2","DOI":"10.1186\/s12885-020-07545-2"},{"key":"10353_CR267","doi-asserted-by":"publisher","unstructured":"Guti\u00e9rrez-G\u00e1lvez, L., Sulleiro, M. V., Guti\u00e9rrez-S\u00e1nchez, C., Garc\u00eda-Nieto, D., Luna, M., P\u00e9rez, E. M., \u2026 & Lorenzo, E. (2023). MoS2-carbon nanodots as a new electrochemiluminescence platform for breast cancer biomarker detection. Biosensors, 13(3), 348. https:\/\/doi.org\/10.3390\/bios13030348","DOI":"10.3390\/bios13030348"},{"issue":"10","key":"10353_CR268","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.urolonc.2025.02.009","volume":"43","author":"F Chen","year":"2025","unstructured":"Chen, F., Simsir, A., & Cheng, L. (2025). Molecular testing in urinary cytology specimens: Current status and future directions. Urologic Oncology, 43(10), 565\u2013578. https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.009","journal-title":"Urologic Oncology"},{"issue":"4","key":"10353_CR269","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3390\/diagnostics12040931","volume":"12","author":"DB Allison","year":"2022","unstructured":"Allison, D. B., Zhang, M. L., Vohra, P., & VandenBussche, C. J. (2022). The diagnostic dilemma of urothelial tissue fragments in urinary tract cytology specimens. Diagnostics, 12(4), 931. https:\/\/doi.org\/10.3390\/diagnostics12040931","journal-title":"Diagnostics"},{"key":"10353_CR270","doi-asserted-by":"publisher","unstructured":"Dudley, J. C., Schroers-Martin, J., Lazzareschi, D. V., Shi, W. Y., Chen, S. B., Esfahani, M. S., \u2026 & Diehn, M. (2019). Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discovery, 9(4), 500\u2013509. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0825","DOI":"10.1158\/2159-8290.CD-18-0825"},{"key":"10353_CR271","doi-asserted-by":"publisher","unstructured":"Zhang, R., Zang, J., Xie, F., Zhang, Y., Wang, Y., Jing, Y., \u2026 & Chen, H. (2021). Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer. The Journal of Urology, 206(4), 873\u2013884. https:\/\/doi.org\/10.1097\/JU.0000000000001878","DOI":"10.1097\/JU.0000000000001878"},{"key":"10353_CR272","doi-asserted-by":"publisher","unstructured":"Lee, D. H., Yoon, H., Park, S., Kim, J. S., Ahn, Y.-H., Kwon, K., \u2026 & Kim, K. H. (2018). Urinary exosomal and cell-free DNA detects somatic mutation and copy number alteration in urothelial carcinoma of bladder. Scientific Reports, 8(1), 14707. https:\/\/doi.org\/10.1038\/s41598-018-32900-6","DOI":"10.1038\/s41598-018-32900-6"},{"issue":"27","key":"10353_CR273","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.2174\/0109298673302140240627053904","volume":"32","author":"O Abazari","year":"2025","unstructured":"Abazari, O., Dayati, P., Shahidi, M., ZavarReza, J., Rahmanian, M., & Naghib, S. M. (2025). Exploring a desirable quadr-mRNAs panel for non-invasive and ultrasensitive bladder cancer diagnosis: In-silico and clinical studies. Current Medicinal Chemistry, 32(27), 5843\u20135860. https:\/\/doi.org\/10.2174\/0109298673302140240627053904","journal-title":"Current Medicinal Chemistry"},{"key":"10353_CR274","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1427122","volume":"14","author":"J Peng","year":"2024","unstructured":"Peng, J., Tang, Z., Li, T., Pan, X., Feng, L., & Long, L. (2024). Contrast-enhanced computed tomography-based radiomics nomogram for predicting HER2 status in urothelial bladder carcinoma. Frontiers in Oncology, 14, Article 1427122. https:\/\/doi.org\/10.3389\/fonc.2024.1427122","journal-title":"Frontiers in Oncology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10353-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10353-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10353-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:14:09Z","timestamp":1783008849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10353-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":274,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["10353"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10353-y","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xinan Sheng has the following potential conflicts of interest to disclose: non-profit consultant for Pfizer, Novartis, Astellas, AstraZeneca, Bayer, MSD, RemeGen, and Junshi Biosciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}